var title_f2_35_2608="Duck waddle";
var content_f2_35_2608=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Duck waddle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This maneuver assesses the stability of the knee and the ability to perform complex tasks. The patient is asked to squat and then move forward, transferring the weight back and forth from the right to the left side, while remaining in a squatting position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_35_2608=[""].join("\n");
var outline_f2_35_2608=null;
var title_f2_35_2609="Left upper lobe atelectasis A";
var content_f2_35_2609=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Left upper lobe atelectasis in a child with cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiographs of an eight-year-old girl with cystic fibrosis, recent wheezing, increased cough and secretions, and diminished breath sounds in left upper lobe. Upright frontal radiograph reveals relatively increased opacity of the left lung and indistinctness of the left mediastinal border. The lateral view shows anterior displacement of the major fissure caused by left upper lobe atelectasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_35_2609=[""].join("\n");
var outline_f2_35_2609=null;
var title_f2_35_2610="Patient information: Tattoos and body piercings (The Basics)";
var content_f2_35_2610=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?4/23/4466\">",
"         Patient information: Cellulitis and erysipelas (skin infections) (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Tattoos and body piercings (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H189548213\">",
"      <span class=\"h1\">",
"       How are tattoos done?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Tattoos are done with needles that inject dyes directly under the skin. The needles pierce the skin over and over again until the tattoo is completely drawn. Tattoo artists do not use anesthesia, so anyone having a tattoo must withstand the pain of the needles. The dyes that tattoo artists use are not regulated by the government. They can contain salts, metals, and lots of different chemicals. People sometimes have a bad reaction to these dyes.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H189548228\">",
"      <span class=\"h1\">",
"       How are body piercings done?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ear piercings can be done using spring-loaded piercing guns that shoot a stud through the ear. Most other piercings are done with a hollow needle. Usually, the person doing the piercing will put the needle through the desired body part to make the hole. Then he or she will insert a piece of jewelry to keep the hole open.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H189548243\">",
"      <span class=\"h1\">",
"       Can tattoos or body piercings cause medical problems?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Each type of body art can cause its own set of problems.",
"     </p>",
"     <p>",
"      People who get tattoos can get infections, including some serious infections, such as HIV (which causes AIDS), or hepatitis B or C (which cause liver disease). These infections happen because tattoo needles are not always cleaned well between uses. If you get a tattoo and the needles have not been cleaned well, the blood of the people who got tattoos before you can get injected under your skin.",
"     </p>",
"     <p>",
"      People who get tattoos can also have allergic reactions to the tattoo dyes. If they ever have a test called an MRI (which creates pictures of the inside of the body), they can also have skin pain or burning during the test. That&rsquo;s because tattoo dyes sometimes contain metals, which heat up or move around while inside the MRI machine.",
"     </p>",
"     <p>",
"      People who have body piercings can get infections either in the skin near the piercing, or infections that affect the whole body. They can also develop dental problems if they have a piercing in the tongue or lips.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H189548260\">",
"      <span class=\"h1\">",
"       Is there any way to reduce the risks of tattoos and piercings?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you are sure you want to get a tattoo or a body piercing, here are some things you can do to reduce the risks:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Visit a few tattoo or piercing salons and watch the artists at work. That way you can see what&rsquo;s involved and whether the artists are clean. Choose a salon that has been in business for a while. Do not go to stands at carnivals, flea markets, rock concerts, or other temporary locations.",
"       </li>",
"       <li>",
"        Keep in mind that most good tattoo or piercing salons will only serve people who are at least 18 years old. Most do not accept a parent&rsquo;s note as proof that the parent approves of the tattoo or piercing. Instead they want the parent to come to the salon with their child. If you are younger than 18, it&rsquo;s actually a good idea to bring your parent along. That way, he or she can make sure that the tattoo or piercing is done as safely as possible.",
"       </li>",
"       <li>",
"        Talk to other people who have had what you want done. Find out what it was like for them and ask if they have any regrets. Remember, there&rsquo;s no reason do anything in a hurry. A tattoo or piercing is something you will have to live with for the rest of your life. Take your time deciding what you want to do. Whatever you do, do NOT get a tattoo or piercing when you are drunk or high. Also, do NOT get a tattoo or piercing while you are pregnant.",
"       </li>",
"       <li>",
"        Make sure you think carefully about your choice of tattoo or piecing and its location. You might want to be able to hide your body art in certain situations.",
"       </li>",
"       <li>",
"        Remember that a tattoo or piercing can cause serious pain. You will not get anesthesia while it is being done.",
"       </li>",
"       <li>",
"        If you are getting a tattoo, make sure the tattoo artist:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Washes his or her hands with soap and water and then puts on gloves",
"       </li>",
"       <li>",
"        Uses sterile water (usually in specially marked bottles), NOT tap water to rinse the equipment or the area to be tattooed",
"       </li>",
"       <li>",
"        Wipes the area to be tattooed with alcohol or iodine",
"       </li>",
"       <li>",
"        Uses disposable cups to hold the dyes for the tattoo",
"       </li>",
"       <li>",
"        Uses sterile needles (in individually wrapped packages that are opened in front of you)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H189548277\">",
"      <span class=\"h1\">",
"       What should I do after getting a tattoo or piercing?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most important thing to do is to keep the area that was tattooed or pierced clean. Use soap and water to wash the area every day, but try not to touch it at other times until it heals.",
"     </p>",
"     <p>",
"      If you got a piercing, do NOT use the special solutions that are sold in shopping malls and other places to clean piercings. These solutions are not good at getting rid of many bacteria, and they can even carry their own bacteria. Soap and water is a better choice.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H189548294\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if the body part that was tattooed or pierced swells, turns red, feels hot, or starts to ooze pus or smell bad. You should also see a doctor or nurse if you get a fever.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H189548309\">",
"      <span class=\"h1\">",
"       What if I want to have my tattoo removed?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is possible to have a tattoo removed with special lasers. But the process takes several visits, and it can cause problems of its own. It can cause the skin to change color or to get irritated or swollen. Plus it can be expensive&mdash;usually much more expensive than getting a tattoo in the first place.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H189548324\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/23/4466?source=see_link\">",
"       Patient information: Cellulitis and erysipelas (skin infections) (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?2/35/2610?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87357 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_35_2610=[""].join("\n");
var outline_f2_35_2610=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H189548213\">",
"      How are tattoos done?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H189548228\">",
"      How are body piercings done?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H189548243\">",
"      Can tattoos or body piercings cause medical problems?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H189548260\">",
"      Is there any way to reduce the risks of tattoos and piercings?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H189548277\">",
"      What should I do after getting a tattoo or piercing?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H189548294\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H189548309\">",
"      What if I want to have my tattoo removed?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H189548324\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/23/4466?source=related_link\">",
"      Patient information: Cellulitis and erysipelas (skin infections) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_35_2611="Cobb angle measurement 2";
var content_f2_35_2611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cobb angle measurement of kyphosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 464px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kado DM, Christianson L, Palermo L, et al. Comparing a supine radiologic versus standing clinical measurement of kyphosis in older women: the Fracture Intervention Trial. Spine 2006; 31:463. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_35_2611=[""].join("\n");
var outline_f2_35_2611=null;
var title_f2_35_2612="Pityriasis light and dark skin PI";
var content_f2_35_2612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F65314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F65314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Pityriasis rosea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pityriasis rosea is a skin rash that sometimes starts with a single large patch (see arrow). Many smaller spots appear within a few days. In people with light skin, the spots are pink or salmon-colored. In people with dark skin, the spots are a red-brown color or darker than their skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     (A) Courtesy of John T Crissey, MD.",
"     <br>",
"      (B) Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_35_2612=[""].join("\n");
var outline_f2_35_2612=null;
var title_f2_35_2613="Midodrine: Drug information";
var content_f2_35_2613=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Midodrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/26/43428?source=see_link\">",
"    see \"Midodrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F196540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amatine&reg;;",
"     </li>",
"     <li>",
"      Apo-Midodrine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F196568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha",
"      <sub>",
"       1",
"      </sub>",
"      Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F196542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Orthostatic hypotension:",
"     </b>",
"     Oral: 10 mg 3 times/day during daytime hours (every 3-4 hours) when patient is upright (maximum: 40 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prevention of hemodialysis-induced hypotension (unlabeled use):",
"     </b>",
"     Oral: 2.5-10 mg given 15-30 minutes prior to dialysis session (Cruz, 1998; KDOQI, 2005; Prakash, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Vasovagal syncope (unlabeled use):",
"     </b>",
"     Oral: Initial: 5 mg 3 times/day during daytime hours (every 6 hours) increased up to 15 mg/dose if necessary (Perez-Lugones, 2001; Ward, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F196543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F196544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Orthostatic hypotension: 2.5 mg 3 times/day; gradually increase as tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Dialyzable; dose after hemodialysis unless used for prevention of hemodialysis-induced hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F196518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 2.5 mg, 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F196504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F196520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses may be given in approximately 3- to 4-hour intervals (eg, shortly before or upon rising in the morning, at midday, in the late afternoon not later than 6 PM). Avoid dosing after the evening meal or within 4 hours of bedtime. Continue therapy only in patients who appear to attain symptomatic improvement during initial treatment. Standing systolic blood pressure may be elevated 15-30 mm Hg at 1 hour after a 10 mg dose. Some effect may persist for 2-3 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F196519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Orphan drug:",
"     </b>",
"     Treatment of symptomatic orthostatic hypotension",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F196564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of urinary incontinence; vasovagal syncope; prevention of dialysis-induced hypotension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F196575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Midodrine may be confused with Midrin&reg;, minoxidil",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ProAmatine may be confused with protamine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F196566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Supine hypertension (7% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Piloerection (13%), pruritus (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary urgency, retention, or polyuria, dysuria (up to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills (5%), pain (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anxiety, backache, canker sore, confusion, dizziness, dry skin, erythema multiforme, facial flushing, flatulence, flushing, GI distress, headache, heartburn, hyperesthesia, insomnia, ICP increased, leg cramps, nausea, somnolence, visual field defect, weakness, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F196523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to midodrine or any component of the formulation; severe organic heart disease; acute renal failure; urinary retention; pheochromocytoma; thyrotoxicosis; persistent and significant supine hypertension",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F196508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bradycardia: May slow heart rate primarily due to vagal reflex. Use caution when administered concurrently with negative chronotropes (eg, digoxin, beta blockers).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: May cause hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Desglymidodrine, the active metabolite, is primarily renally excreted; assess renal function prior to initial dose; use with caution in patients with renal impairment and initiate with a reduced dose; contraindicated in patients with acute renal failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Urinary retention: Use with caution in patients with urinary retention; reduce initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual problems: Use with caution in patients with visual problems, especially if receiving fludrocortisone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: Indicated for patients for whom orthostatic hypotension significantly impairs their daily life despite standard clinical care.",
"     </b>",
"     Use is not recommended with supine hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring: Monitor renal and hepatic function prior to and periodically during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F196513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: May enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F196514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F196525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increased rate of embryo resorption and decreased fetal weight were observed in animal studies. Use during pregnancy should be avoided unless the potential benefit outweighs the risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F196548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk is unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F196524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Midodrine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $120.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $242.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $483.64",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F196516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; renal and hepatic function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F196526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Gutron (AR, AT, BG, CH, CL, CN, CZ, DE, FR, GR, HK, HN, HU, IL, IT, NL, NZ, PL, PT, RU, SG, TW, UY);",
"     </li>",
"     <li>",
"      Metligine (JP);",
"     </li>",
"     <li>",
"      Midodrine Hydrochloride (ID);",
"     </li>",
"     <li>",
"      Midon (IE);",
"     </li>",
"     <li>",
"      Midorine (TW);",
"     </li>",
"     <li>",
"      Midron (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F196507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Midodrine forms an active metabolite, desglymidodrine, which is an alpha",
"     <sub>",
"      1",
"     </sub>",
"     -agonist. This agent increases arteriolar and venous tone resulting in a rise in standing, sitting, and supine systolic and diastolic blood pressure in patients with orthostatic hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F196522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     (desglymidodrine): &lt;1.6 L/kg; poorly across membrane (eg, blood-brain barrier)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Minimal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and many other tissues; midodrine is a prodrug which undergoes rapid deglycination to desglymidodrine (active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Desglymidodrine: 93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Desglymidodrine: ~3-4 hours; Midodrine: 25 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Desglymidodrine: 1-2 hours; Midodrine: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (Midodrine: Insignificant; Desglymidodrine: 80% by active renal secretion)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brignole M, Alboni P, Benditt DG, et al, &ldquo;Guidelines on Management (Diagnosis and Treatment) of Syncope - Update 2004,&rdquo;",
"      <i>",
"       Europace",
"      </i>",
"      , 2004, 6(6):467-537.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/35/2613/abstract-text/15519256/pubmed\" id=\"15519256\" target=\"_blank\">",
"        15519256",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cruz DN, Mahnensmith RL, Brickel HM, et al, &ldquo;Midodrine is Effective and Safe Therapy for Intradialytic Hypotension Over 8 Months of Follow-up,&rdquo;",
"      <i>",
"       Clin Nephrol",
"      </i>",
"      , 1998, 50(2):101-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/35/2613/abstract-text/9725781/pubmed\" id=\"9725781\" target=\"_blank\">",
"        9725781",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perez-Lugones A, Schweikert R, Pavia S, et al, &ldquo;Usefulness of Midodrine in Patients With Severely Symptomatic Neurocardiogenic Syncope: A Randomized Control Study,&rdquo;",
"      <i>",
"       J Cardiovasc Electrophysiol",
"      </i>",
"      , 2001, 12(8):935-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/35/2613/abstract-text/11513446/pubmed\" id=\"11513446\" target=\"_blank\">",
"        11513446",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prakash S, Garg AX, Heidenheim AP, et al, &ldquo;Midodrine Appears to be Safe and Effective for Dialysis-Induced Hypotension: A Systematic Review,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2004, 19(10):2553-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ward CR, Gray JC, Gilroy JJ, et al, &ldquo;Midodrine: A Role in the Management of Neurocardiogenic Syncope,&rdquo;",
"      <i>",
"       Heart",
"      </i>",
"      , 1998, 79(1):45-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/35/2613/abstract-text/9505918/pubmed\" id=\"9505918\" target=\"_blank\">",
"        9505918",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Kidney Foundation, &ldquo;KDOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients,&rdquo; Available at  file://www.kidney.org/professionals/KDOQI/guidelines_cvd/index.htm",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9651 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-125.69.132.100-32DA4B247A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_35_2613=[""].join("\n");
var outline_f2_35_2613=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709087\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196540\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196568\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196542\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196543\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196544\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196518\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196504\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196520\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196519\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196564\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196575\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196566\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196523\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196508\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299710\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196513\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196514\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196525\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196548\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196524\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196516\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196526\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196507\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196522\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9651\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9651|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/26/43428?source=related_link\">",
"      Midodrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_35_2614="Letter cancellation test";
var content_f2_35_2614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F63183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F63183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Letter cancellation test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 500px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The&nbsp; Letter Cancellation Test is used to evaluate the presence, pattern,&nbsp;and severity of visual scanning deficits. In this example, the patient correctly crossed out all instances of&nbsp;the letter A.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_35_2614=[""].join("\n");
var outline_f2_35_2614=null;
var title_f2_35_2615="Dextromethorphan poisoning: Treatment";
var content_f2_35_2615=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dextromethorphan poisoning: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/35/2615/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/35/2615/contributors\">",
"     Chris Rosenbaum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/35/2615/contributors\">",
"     Edward W Boyer, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/35/2615/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/35/2615/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/35/2615/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/35/2615/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/35/2615/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     Dextromethorphan",
"    </a>",
"    (d-3-methoxy-N-methylmorphinan, DXM) is an over-the-counter cough suppressant that is commonly diverted for illicit recreational use among teenagers and young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2615/abstract/1\">",
"     1",
"    </a>",
"    ]. While structurally related to the opiate receptor agonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    , DXM in overdose expresses a unique combination of euphoric, stimulant, and dissociative effects in older children and adolescents. Rarely, DXM poisoning is associated with profound coma and, in young children, respiratory depression that is responsive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2615/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Because of the marked increase in misuse of this substance in adolescents, clinicians should have a thorough understanding of clinical presentations of this drug, its toxicity, and the principles of management [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2615/abstract/1,4-6\">",
"     1,4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    poisoning will be reviewed here. The epidemiology, pertinent pharmacology, and clinical features of dextromethorphan poisoning are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17353?source=see_link\">",
"     \"Dextromethorphan poisoning: Epidemiology, pharmacology and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Related issues such as methylenedioxymethamphetamine (MDMA) abuse, serotonin syndrome, anticholinergic poisoning,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    intoxication, phencyclidine (PCP) intoxication, ethanol intoxication, and a general approach to management of the poisoned patient are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=see_link\">",
"     \"MDMA (ecstasy) intoxication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=see_link\">",
"     \"Anticholinergic poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40935?source=see_link\">",
"     \"Ketamine poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/570?source=see_link\">",
"     \"Phencyclidine (PCP) intoxication in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2137?source=see_link\">",
"     \"Ethanol intoxication in children: Clinical features, evaluation, and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for care of children and adults with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    poisoning are derived from case series and reports and are driven by physical findings. The treatment of dextromethorphan poisoning is primarily supportive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17353?source=see_link&amp;anchor=H9#H9\">",
"     \"Dextromethorphan poisoning: Epidemiology, pharmacology and clinical features\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, to careful assessment and support of airway, breathing, and circulation as needed, the clinician should anticipate and aggressively manage dissociative signs and symptoms (eg, psychosis, hallucinations, agitation), hyperthermia, rhabdomyolysis, and dehydration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2615/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Specific antidotal therapy may be necessary for patients who manifest coma and respiratory depression, serotonin syndrome, or concomitant anticholinergic poisoning. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Naloxone'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Other toxins'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Restraint and sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early management of agitation or violent behavior is essential to prevent patient and staff injury. The emergency provider should exclude life-threatening hypoglycemia and hypoxia as contributing factors to agitation as soon as is safely possible. Verbal reassurance and placement of the patient in a calm, quiet, and subdued environment may suffice in the adolescent or adult with mild to moderate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    intoxication.",
"   </p>",
"   <p>",
"    In the markedly agitated or floridly psychotic patient, initial control often requires supine physical restraint that is rapidly followed by sedation with intravenous or intramuscular benzodiazepines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    0.1",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    maximum initial dose: 2 mg, repeat in 10 to 30 minutes as needed). Parenteral neuroleptic medication (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ) should be avoided in patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    overdose because it may exacerbate hyperthermia or anticholinergic symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=see_link\">",
"     \"Assessment and management of the acutely agitated or violent adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4666?source=see_link&amp;anchor=H20#H20\">",
"     \"Emergency department evaluation of acute onset psychosis in children\", section on 'Physical restraint and sedation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active cooling measures should be instituted promptly in patients with elevated rectal temperature and with other findings that indicate malignant hyperthermia (eg, pulmonary edema, rhabdomyolysis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link&amp;anchor=H9#H9\">",
"     \"Severe hyperthermia (heat stroke) in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Augmentation of evaporative cooling is considered the treatment modality of choice because it is effective, noninvasive, and easily performed. The naked patient is sprayed with a mist of lukewarm water while air is circulated with large fans. Shivering may be suppressed with intravenous benzodiazepines such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    (5 mg IV) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    (1-2 mg IV). Cold inspired oxygen, cold gastric lavage, cooling blankets, and cold intravenous fluids may be helpful adjuncts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link&amp;anchor=H10#H10\">",
"     \"Severe hyperthermia (heat stroke) in adults\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link&amp;anchor=H18#H18\">",
"     \"Heat stroke in children\", section on 'Rapid cooling'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some experts advocate that patients with marked hyperthermia (temperature &gt;40&ordm;C) might benefit from rapid sequence intubation followed by prolonged paralysis to stop heat generation from muscle activity.",
"   </p>",
"   <p>",
"    There is NO ROLE for antipyretic agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in the management of drug-induced hyperthermia, since the underlying mechanism does not involve a change in the hypothalamic temperature set-point. Alcohol sponge baths should also be avoided because large amounts of the drug may be absorbed through dilated cutaneous vessels and produce toxicity",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthermia, agitation, seizures, and muscle rigidity may lead to muscle cell breakdown (rhabdomyolysis) with significant risk for renal failure. Patients with rhabdomyolysis typically present with the triad of pigmented granular casts in the urine, a red to brown color of the urine supernatant, and a marked elevation in the plasma level of creatine kinase (CK). Primary treatment goals consist of (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluid repletion with normal saline infusion (20 to 40",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour up to 1 to 2 L per hour); the emergency provider should closely monitor urine output with the goal of maintaining a minimum urine flow of 4",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour; 200 mL per hour in adults. Once diuresis is established, alkalinization of the urine and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      diuresis is commonly employed but efficacy is uncertain.",
"     </li>",
"     <li>",
"      Evaluation for significant electrolyte abnormalities (hyperkalemia, hyperphosphatemia, and hypocalcemia); management of hyperkalemia is of particular importance. Hypocalcemia is usually transient and calcium administration should be avoided unless severe symptoms (eg, tetany) are present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Serotonin syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to supportive care aimed at agitation and hyperthermia as described above, patients suspected of serotonin syndrome frequently require aggressive sedation with benzodiazepines (",
"    <a class=\"graphic graphic_table graphicRef73400 \" href=\"UTD.htm?9/53/10077\">",
"     table 1",
"    </a>",
"    ). In severe cases, serotonin receptor blockade with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"     cyproheptadine",
"    </a>",
"    may be indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Seizures are best managed with a benzodiazepine (eg, 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    , maximum dose: 2 mg; repeat every 2 to 3 minutes up to 3 doses).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     Phenobarbital",
"    </a>",
"    in an initial dose of 15 to 20 is preferred to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    as second line treatment if seizures persist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=see_link\">",
"     \"Management of status epilepticus in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=see_link\">",
"     \"Status epilepticus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GI DECONTAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     Dextromethorphan",
"    </a>",
"    and other components of over-the-counter cough medications bind well to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC), the primary means of decontamination in overdose.",
"   </p>",
"   <p>",
"    We suggest that patients who ingest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    -containing medicines and who present within one hour of known or suspected ingestion receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) (1",
"    <span class=\"nowrap\">",
"     g/kg,",
"    </span>",
"    maximum dose 50 grams) by mouth or nasogastric tube. AC should be withheld in patients who are sedated and may not be able to protect their airway, unless endotracheal intubation is performed first. However, endotracheal intubation should not be performed solely for the purpose of giving AC. The greatest benefit occurs if AC is given within one hour. The efficacy of AC as a function of time from ingestion is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link&amp;anchor=H10032558#H10032558\">",
"     \"Decontamination of poisoned children\", section on 'Efficacy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link&amp;anchor=H26755739#H26755739\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Evidence of efficacy and adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommendation of AC administration following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    overdose derives from indirect evidence of benefit in volunteers, animal studies, and evidence of benefit following ingestions of other medications. Because of adverse effects, such as vomiting and dehydration, the combination of a cathartic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    ) and AC should be used sparingly, if at all, and only a single dose of a cathartic should be given to any patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link&amp;anchor=H27#H27\">",
"     \"Decontamination of poisoned children\", section on 'Cathartics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link&amp;anchor=H10032467#H10032467\">",
"     \"Decontamination of poisoned children\", section on 'Activated charcoal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link&amp;anchor=H18993761#H18993761\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Activated charcoal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link&amp;anchor=H18993978#H18993978\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Cathartics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend not performing gastric emptying by gastric lavage or by syrup of ipecac-induced emesis in patients who ingest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    . This recommendation is based on randomized controlled trials showing minimal benefit and possible risk to patients who undergo gastric emptying after poisoning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link\">",
"     \"Decontamination of poisoned children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NALOXONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     Naloxone",
"    </a>",
"    administration has reversed respiratory depression and coma following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    poisoning in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2615/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Patients with deep coma and respiratory depression should receive intravenous naloxone (0.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum initial dose: 2 mg). Some patients may require total doses of naloxone approaching 10 mg to fully reverse symptoms of respiratory depression [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2615/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients who improve after naloxone administration still warrant hospital admission and intensive monitoring for recurrence of symptoms. If altered mental status and respiratory depression recur, we suggest the administration of additional intermittent doses, as needed, rather than a continuous infusion.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     Naloxone",
"    </a>",
"    administration should not delay the timely provision of supportive care (eg, bag-valve-mask ventilation with 100 percent oxygen) in patients who do not initially respond.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OTHER TOXINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    , over-the-counter cough formulations frequently contain other pharmaceutical agents whose toxicity may complicate dextromethorphan poisoning, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=see_link\">",
"     chlorpheniramine",
"    </a>",
"    or other antihistamines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Acetaminophen toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    levels in the possible toxic range, based on the Rumack-Matthew nomogram (",
"    <a class=\"graphic graphic_figure graphicRef83590 \" href=\"UTD.htm?24/56/25472\">",
"     figure 1",
"    </a>",
"    ) should receive oral or intravenous antidote therapy with N-acetylcysteine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=see_link\">",
"     \"Management of acetaminophen (paracetamol) poisoning in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anticholinergic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     Dextromethorphan",
"    </a>",
"    intoxication is frequently complicated by anticholinergic poisoning. Both dextromethorphan and anticholinergic poisoning have similar presenting signs and symptoms that makes treatment decisions difficult. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17353?source=see_link&amp;anchor=H16#H16\">",
"     \"Dextromethorphan poisoning: Epidemiology, pharmacology and clinical features\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17353?source=see_link&amp;anchor=H9#H9\">",
"     \"Dextromethorphan poisoning: Epidemiology, pharmacology and clinical features\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Agitation and delirium caused by anticholinergic poisoning is initially treated with benzodiazepines (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    0.1 mg; maximum dose: 2 mg). Some experts recommend that patients with anticholinergic poisoning manifesting both peripheral signs (eg, flushing, dry skin, hyperthermia) and central effects (agitated delirium, seizures) receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40372?source=see_link\">",
"     physostigmine",
"    </a>",
"    . However, this recommendation is controversial and consultation with a medical toxicologist or regional poison center should be obtained before physostigmine is given. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=see_link\">",
"     \"Anticholinergic poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pseudoephedrine toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"     Pseudoephedrine",
"    </a>",
"    and other alpha1 adrenergic agonists can precipitate a hypertensive emergency in overdose that may require emergent administration of intravenous antihypertensive medication (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    0.1",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    maximum dose: 5 mg). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of hypertensive emergencies and urgencies in children\", section on 'Blood pressure management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18853?source=see_link&amp;anchor=H13#H13\">",
"     \"Drug treatment of hypertensive emergencies\", section on 'Phentolamine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with uncomplicated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    (DXM) poisoning have resolution of symptoms within 4 to 6 hours after ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2615/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Patients with complicated courses marked by hyperthermia, rhabdomyolysis, or serotonin syndrome warrant intensive care until symptoms resolve. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Supportive care'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who are suicidal require psychiatric evaluation prior to discharge and should also be carefully evaluated for coingestions including the measurement of an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    level.",
"   </p>",
"   <p>",
"    Patients who are asymptomatic for 6 hours after ingestion of DXM, who have nontoxic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    levels, and who are not suicidal, may be discharged home.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     Dextromethorphan",
"    </a>",
"    (d-3-methoxy-N-methylmorphinan, DXM) is an over-the-counter cough suppressant that is commonly diverted for illicit recreational use among teenagers and young adults. While structurally related to the opiate receptor agonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    , DXM in overdose expresses a unique combination of euphoric, stimulant, and dissociative effects in older children and adolescents. Rarely, DXM poisoning is associated with profound coma and, in young children, respiratory depression that is responsive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17353?source=see_link&amp;anchor=H2#H2\">",
"     \"Dextromethorphan poisoning: Epidemiology, pharmacology and clinical features\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"       dextromethorphan",
"      </a>",
"      poisoning is primarily supportive. In addition, to careful assessment and support of airway, breathing, and circulation as needed, the clinician should anticipate and aggressively manage agitation, hyperthermia, rhabdomyolysis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      serotonin syndrome when they occur. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients who ingest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"       dextromethorphan",
"      </a>",
"      -containing medicines and who present within one hour of known or suspected ingestion receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (AC) (1",
"      <span class=\"nowrap\">",
"       g/kg;",
"      </span>",
"      maximum dose: 50 grams) by mouth or nasogastric tube (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Charcoal should be withheld in patients who are sedated and may not be able to protect their airway, unless endotracheal intubation is performed first. However, endotracheal intubation should not be performed solely for the purpose of giving charcoal. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'GI decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients who ingest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"       dextromethorphan",
"      </a>",
"      NOT undergo gastric emptying procedures (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'GI decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with deep coma and respiratory depression should receive intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      (0.1",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum initial dose: 2 mg). Some patients may require total doses of naloxone approaching 10 mg to adequately reverse symptoms. Naloxone administration should not delay the timely provision of supportive care (eg, bag-valve-mask ventilation with 100 percent oxygen) in patients with respiratory depression. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Naloxone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"       dextromethorphan",
"      </a>",
"      , over-the-counter cough formulations frequently contain other pharmaceutical agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=see_link\">",
"       chlorpheniramine",
"      </a>",
"      or other antihistamines,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"       pseudoephedrine",
"      </a>",
"      ) whose toxicity may complicate dextromethorphan poisoning and require specific treatment. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Other toxins'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2615/abstract/1\">",
"      Kirages TJ, Sul&eacute; HP, Mycyk MB. Severe manifestations of coricidin intoxication. Am J Emerg Med 2003; 21:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2615/abstract/2\">",
"      Graudins A, Fern RP. Acute dystonia in a child associated with therapeutic ingestion of a dextromethorphan containing cough and cold syrup. J Toxicol Clin Toxicol 1996; 34:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2615/abstract/3\">",
"      Warden CR, Diekema DS, Robertson WO. Dystonic reaction associated with dextromethorphan ingestion in a toddler. Pediatr Emerg Care 1997; 13:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2615/abstract/4\">",
"      Henretig, F, Cugini, D, Dubin, D. Dextromethorphan overdose in children. Vet Hum Toxicol 1988; 3:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2615/abstract/5\">",
"      Wolfe TR, Caravati EM. Massive dextromethorphan ingestion and abuse. Am J Emerg Med 1995; 13:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2615/abstract/6\">",
"      Schneider SM, Michelson EA, Boucek CD, Ilkhanipour K. Dextromethorphan poisoning reversed by naloxone. Am J Emerg Med 1991; 9:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2615/abstract/7\">",
"      Shaul WL, Wandell M, Robertson WO. Dextromethorphan toxicity: reversal by naloxone. Pediatrics 1977; 59:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2615/abstract/8\">",
"      Boyer EW. Dextromethorphan abuse. Pediatr Emerg Care 2004; 20:858.",
"     </a>",
"    </li>",
"    <li>",
"     Boyer E. Dissociative agents: Phencyclidine, ketamine, dextromethorphan. In: Haddad and Wincehster's Clinical Management of Poisoning and Drug Overdose, 4th, Shannon MW, Borron SW, Burns MJ.  (Eds), Saunders, Philadelphia 2007. p.776.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2615/abstract/10\">",
"      LoVecchio F, Pizon A, Matesick L, O'Patry S. Accidental dextromethorphan ingestions in children less than 5 years old. J Med Toxicol 2008; 4:251.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6492 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-BC6E475435-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_35_2615=[""].join("\n");
var outline_f2_35_2615=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Restraint and sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GI DECONTAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NALOXONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OTHER TOXINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acetaminophen toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anticholinergic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pseudoephedrine toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6492\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6492|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/56/25472\" title=\"figure 1\">",
"      Acetaminophen poisoning nomogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6492|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/53/10077\" title=\"table 1\">",
"      Serotonin syndrome - Rapid overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=related_link\">",
"      Anticholinergic poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=related_link\">",
"      Assessment and management of the acutely agitated or violent adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17353?source=related_link\">",
"      Dextromethorphan poisoning: Epidemiology, pharmacology and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18853?source=related_link\">",
"      Drug treatment of hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4666?source=related_link\">",
"      Emergency department evaluation of acute onset psychosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2137?source=related_link\">",
"      Ethanol intoxication in children: Clinical features, evaluation, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=related_link\">",
"      Heat stroke in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40935?source=related_link\">",
"      Ketamine poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=related_link\">",
"      MDMA (ecstasy) intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=related_link\">",
"      Management of acetaminophen (paracetamol) poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=related_link\">",
"      Management of hypertensive emergencies and urgencies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=related_link\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/570?source=related_link\">",
"      Phencyclidine (PCP) intoxication in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_35_2616="Muscles of the anterior abdominal wall";
var content_f2_35_2616=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F72219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F72219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Muscles of the anterior abdominal wall",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 691px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_35_2616=[""].join("\n");
var outline_f2_35_2616=null;
var title_f2_35_2617="Approach to the patient with weight loss";
var content_f2_35_2617=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with weight loss",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/35/2617/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/35/2617/contributors\">",
"     Arthur T Evans, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/35/2617/contributors\">",
"     Renuka Gupta, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/35/2617/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/35/2617/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/35/2617/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/35/2617/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/35/2617/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H88396380\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss is the result of decreased energy intake or increased energy expenditure. Weight loss may be classified as voluntary or involuntary. Progressive involuntary weight loss often indicates a serious medical or psychiatric illness. Voluntary weight loss in overweight or obese individuals is benign in most instances. However, in someone who is not overweight, voluntary weight loss is usually a manifestation of psychiatric disease.",
"   </p>",
"   <p>",
"    This topic will discuss the approach to weight loss in the adult patient. Weight loss or inadequate weight gain in children and adolescents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/12/14538?source=see_link\">",
"     \"Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38233?source=see_link\">",
"     \"Poor weight gain in children older than two years of age\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396387\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically important weight loss is traditionally defined as loss of more than 5 percent of usual body weight over six months.",
"   </p>",
"   <p>",
"    In the past, an absolute weight loss of 10 pounds (4.5 kg) or more was also accepted as a criterion for significant weight loss. However, this definition is inadequate given the increase in average body size in most developed countries. These relatively arbitrary historical standards need more rigorous assessment since traditional definitions do not distinguish between losses to lean body mass (sarcopenia) or body fat, which can lead to important clinical outcomes. For example, loss of muscle mass relative to body fat in the elderly leads to frailty and functional decline [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/1\">",
"     1",
"    </a>",
"    ]. Conversely, loss of body fat with weight loss is largely associated with improved clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When involuntary weight loss exceeds 10 percent of usual weight (in nonobese persons), the etiology and potential sequelae of weight loss must be investigated. Involuntary weight loss exceeding 20 percent of usual weight is often associated with severe protein-energy malnutrition, nutritional deficiencies, and multiorgan dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396394\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a representative sample of over 9000 adults in the United States (US), 5 percent reported involuntary",
"    <strong>",
"    </strong>",
"    weight loss of at least 5 percent of their usual body weight during the preceding year [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/4\">",
"     4",
"    </a>",
"    ]. An additional 8 percent reported voluntary weight loss of the same magnitude. There were no important differences in weight loss incidence by gender. The strongest independent predictors of involuntary weight loss were age, smoking, and poor self-reported health. None of these risk factors was associated with voluntary weight loss. The strongest independent predictors of voluntary weight loss were higher baseline body mass index (BMI) and higher education level.",
"   </p>",
"   <p>",
"    The majority of people will eventually meet the criteria for significant involuntary weight loss if they live long enough. Many studies, especially of nursing home residents, report a prevalence of weight loss exceeding 50 percent, which is most commonly multifactorial and associated with functional decline [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396401\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of weight loss on mortality is related to whether weight loss is voluntary or involuntary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396408\">",
"    <span class=\"h2\">",
"     Involuntary weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality rates appear to be increased when weight loss is involuntary. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Israeli Ischemic Heart Disease Study of over 10,000 adult men working in the civil service, those who were not dieting but nevertheless lost at least 5 kg over 5 years had an 18 percent increase in total mortality over the next 18 years [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/7\">",
"       7",
"      </a>",
"      ]. The excess mortality was almost entirely explained by increased cardiovascular deaths, even after adjusting for age, baseline cardiovascular risk factors, baseline BMI, and other comorbidities. Cancer mortality was not different between those who lost weight and those who did not.",
"     </li>",
"     <li>",
"      The US National Health and Nutrition Examination Survey (NHANES) II Mortality Study evaluated over 5000 participants age &ge;50 years, who were followed for at least 12 years [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/8\">",
"       8",
"      </a>",
"      ]. Seven percent of the sample reported involuntary weight loss of 5 percent or more over six months. Prevalence increased with age and was also higher among those with obesity. Involuntary weight loss was associated with a 24 percent relative increase in mortality during the follow-up period, even among those with obesity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mortality rates are higher for other specific populations with weight loss. Weight loss among nursing home residents predicts increased mortality, regardless of underlying diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/9-12\">",
"     9-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396415\">",
"    <span class=\"h2\">",
"     Voluntary weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether voluntary weight loss in the general population is associated with reduced mortality. In prospective cohort studies, voluntary weight loss may be associated with a decrease in mortality in overweight and obese individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Patients who lose weight following bariatric surgery have both decreased comorbid illness and mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. However, these studies included specific patient populations undergoing bariatric surgery and cannot be extrapolated to the general population who are losing weight through diet and exercise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link&amp;anchor=H297382#H297382\">",
"     \"Surgical management of severe obesity\", section on 'Reduction in mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396422\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many causes of weight loss, which are classified as voluntary or involuntary (",
"    <a class=\"graphic graphic_table graphicRef69495 \" href=\"UTD.htm?8/61/9181\">",
"     table 1",
"    </a>",
"    ). In the absence of fever or other cause for increased energy expenditure, weight loss is predominantly due to decreased food intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396429\">",
"    <span class=\"h2\">",
"     Involuntary weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive involuntary weight loss often indicates serious medical or psychiatric illness. Any chronic illness affecting any organ system can cause anorexia and weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396437\">",
"    <span class=\"h3\">",
"     Endocrinopathies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396445\">",
"    <span class=\"h4\">",
"     Hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss in hyperthyroidism is due primarily to increased catabolism, but other causes include increased intestinal motility and malabsorption. Most patients have hyperphagia. Some younger patients with mild hyperthyroidism eat enough to actually gain weight. In older patients, however, hyperthyroidism often causes anorexia with accelerated weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The average weight loss in a patient with hyperthyroidism is 16 percent of usual body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/18\">",
"     18",
"    </a>",
"    ]. Weight gain occurs quickly with treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396452\">",
"    <span class=\"h4\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncontrolled diabetes mellitus is a common cause of weight loss with increased appetite, particularly with new-onset type 1 diabetes mellitus. There is a loss in lean body mass as well as loss of extracellular and cellular water due to the osmotic diuresis from glucosuria. The etiology of weight loss in uncontrolled diabetes is likely multifactorial, a combination of anorexia, depression, pain, malabsorption, gastroparesis, and enteropathy. Some reports describe persons who intentionally undertreat their diabetes in order to lose weight [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link\">",
"     \"Diagnosis of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although patients with poorly-controlled or undiagnosed type 2 diabetes can occasionally present with weight loss, weight gain is much more common. However, some patients with type 2 diabetes can occasionally present with diabetic neuropathic cachexia, an unusual and poorly understood syndrome characterized by profound weight loss (as much as 60 percent of body weight) and often severe neuropathic pain of the anterior thighs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The pathophysiology is not clear, especially since there is no strong relationship between glucose control and resolution of weight loss, which usually happens spontaneously after months or years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396459\">",
"    <span class=\"h4\">",
"     Other endocrine disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic primary adrenal insufficiency often presents with significant weight loss, although other associated signs and symptoms are more prominent: dehydration, anorexia, lassitude, fatigue, and weakness. Adrenal insufficiency that is acute or due to hypothalamic or pituitary dysfunction is usually not associated with weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anorexia, nausea, constipation, and polyuria may account for weight loss in patients with the classic clinical manifestations of hyperparathyroidism. However, the majority of patients with primary hyperparathyroidism are asymptomatic and do not have weight loss. This was illustrated by the findings of a meta-analysis of 13 studies, which showed that patients with primary hyperparathyroidism actually weigh more than age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hyperadrenergic state among patients with pheochromocytoma would theoretically cause weight loss with increased appetite, but only 5 percent of patients with pheochromocytomas report weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396466\">",
"    <span class=\"h3\">",
"     Gastrointestinal diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous mechanisms that can cause weight loss in gastrointestinal diseases: anorexia, abdominal pain, early satiety, dysphagia, odynophagia, dysmotility, diarrhea, malabsorption, chronic bleeding, chronic inflammation, chronic ischemia, obstruction, fistulas, malignancies, infections, gastrointestinal resections,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bypasses.",
"   </p>",
"   <p>",
"    In studies that examined the etiologies for involuntary weight loss, benign gastrointestinal causes accounted for 10 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/24-27\">",
"     24-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Malabsorption may cause weight loss with increased or normal appetite. However, celiac disease, one of the more common causes of malabsorption, usually does not present with weight loss or diarrhea in adults. More commonly, adult patients with celiac disease present with iron deficiency or other manifestations of nutritional malabsorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although inflammatory bowel disease can be associated with malabsorption, this is usually a late manifestation. The initial presentation of Crohn's disease often includes significant weight loss, but this is most likely from inflammation and poor appetite. In contrast, early ulcerative colitis usually does not present with weight loss, although marked weight loss occurs with advanced disease.",
"   </p>",
"   <p>",
"    When malabsorption is due to vascular insufficiency, weight loss can be associated with decreased oral intake due to intestinal angina. Mesenteric artery syndrome, however, is almost always a manifestation of weight loss and is not the cause of weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/58/37799?source=see_link\">",
"     \"Superior mesenteric artery syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396473\">",
"    <span class=\"h3\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple mechanisms accounting for weight loss in patients with cancer. Anorexia and weight loss are present in over 50 percent of cancer patients at the time of diagnosis. In a study of patients with lung cancer, anorexia was associated with an average intake deficit of only 300",
"    <span class=\"nowrap\">",
"     kcal/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/28\">",
"     28",
"    </a>",
"    ]. This does not explain the profound weight loss in some patients with cancer cachexia syndrome. Cancer cachexia involves complex metabolic abnormalities that decrease muscle mass and appear to be mediated, at least in part, by tumor necrosis factor alpha and interleukins 1 and 6. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=see_link\">",
"     \"Clinical features and pathogenesis of cancer cachexia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional factors associated with weight loss in malignancy include pain, abdominal distention, nausea, vomiting, infections, dysphagia, early satiety due to hepatosplenic enlargement or malignant obstruction, hypercalcemia, malabsorption, or adverse effects of chemotherapy or radiotherapy.",
"   </p>",
"   <p>",
"    Studies of unexplained involuntary weight loss eventually identify malignancy as the primary cause in 15 to 35 percent of weight loss patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/29\">",
"     29",
"    </a>",
"    ]. One prospective study of involuntary weight loss in the US found that \"occult\" malignancy (ie, not evident after routine studies) is very unusual, with only 1 of 59 patients diagnosed with malignancy over an extended follow-up after an initial evaluation for weight loss was negative [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/24\">",
"     24",
"    </a>",
"    ]. If malignancy is the cause, there is almost always one or more abnormality noted during the standard diagnostic evaluation, and malignancy is usually diagnosed early in the evaluation process. Thus, occult malignancy is a rare cause of unexplained weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396480\">",
"    <span class=\"h3\">",
"     HIV and other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HIV infection have total daily energy expenditure similar to normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Weight loss in patients with HIV infection is usually episodic, occurring with secondary infections or gastrointestinal diseases, and leads to a reduction in energy intake. The lethargy and fatigue that accompany infection may help maintain energy balance and weight [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many chronic infections lead to involuntary weight loss. As an example, many patients with active tuberculosis experience weight loss. For reactivation tuberculosis, significant weight loss is one of the cardinal signs and symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=see_link\">",
"     \"Epidemiology of tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20826?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic infection with hepatitis C virus can also cause weight loss, in addition to nausea, anorexia, and weakness. Drug therapy for hepatitis C can cause or exacerbate weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396487\">",
"    <span class=\"h3\">",
"     Advanced cardiac, pulmonary, and renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hippocrates was among the first to describe weight loss in patients with chronic heart failure (sometimes called &ldquo;cardiac cachexia&rdquo;). Nearly one-half of heart failure patients with New York Heart Association Class III or IV disease lose lean body mass and meet criteria for malnutrition. Weight loss in this population can be associated with anorexia, early satiety, depression, intestinal and liver congestion, and increased levels of cytokines and angiotensin II [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/33\">",
"     33",
"    </a>",
"    ]. The fluid retention associated with chronic heart failure often masks the extensive loss of lean body mass. Weight loss in patients with chronic heart failure is associated with an increased mortality rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link&amp;anchor=H35#H35\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\", section on 'Weight loss and BMI'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Chronic weight loss with malnutrition can also occur with severe chronic lung disease and has been called the pulmonary cachexia syndrome. Estimates of cachexia in severe chronic obstructive pulmonary disease range from 30 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/34\">",
"     34",
"    </a>",
"    ]. Progressive weight loss can occur even with adequate caloric intake due to increased respiratory muscle work and possibly systemic inflammation. Often the weight loss is episodic, associated with exacerbations of lung disease, but without any regain in weight after recovery. Glucocorticoid treatment, systemic inflammation, and immobility contribute to the loss of muscle mass in severe lung disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/39/43639?source=see_link&amp;anchor=H4#H4\">",
"     \"Nutritional support in advanced lung disease\", section on 'Metabolism and caloric intake'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In advanced kidney disease, anorexia and other uremic symptoms usually occur when the glomerular filtration rate (GFR) drops below 15",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    As with heart failure, fluid retention in advanced kidney disease often masks the true loss in lean body mass. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of the management of chronic kidney disease in adults\", section on 'Malnutrition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396501\">",
"    <span class=\"h3\">",
"     Neurologic diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several neurologic illnesses can lead to weight loss, including stroke, dementia, Parkinson disease, and amyotrophic lateral sclerosis. Weight loss may be due to one or more deficits associated with these disorders, such as anorexia, altered cognition, motor dysfunction, and dysphagia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17610?source=see_link\">",
"     \"Medical complications of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=see_link\">",
"     \"Clinical manifestations of Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=see_link&amp;anchor=H21#H21\">",
"     \"Risk factors for dementia\", section on 'Obesity and body mass index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261330794\">",
"    <span class=\"h3\">",
"     Systemic inflammatory disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are reports of older patients with unintentional weight loss who are eventually diagnosed with giant cell (temporal) arteritis but never manifest classic signs or symptoms of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396508\">",
"    <span class=\"h3\">",
"     Psychiatric disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychiatric illness can be a common cause of involuntary weight loss, occurring in 10 to 44 percent of community-dwelling participants [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/25,26,36\">",
"     25,26,36",
"    </a>",
"    ]. In addition, psychiatric disorders, particularly depression, account for 31 to 58 percent of cases of involuntary weight loss in nursing home patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/9,37,38\">",
"     9,37,38",
"    </a>",
"    ]. The independent role of depression in weight loss is difficult to determine due to the frequency of overlapping causes, such as social isolation, physical disabilities, dementia, dysphagia,",
"    <span class=\"nowrap\">",
"     medication/drug",
"    </span>",
"    use, and multiple chronic diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Loss of appetite and involuntary weight loss can also occur in patients with other psychiatric disorders. During the manic phases of bipolar disorder, hyperactivity and preoccupations may interfere with normal eating patterns. In rare circumstances, patients with delusions or paranoia may develop peculiar ideations about food that lead to decreased food intake and subsequent weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=see_link\">",
"     \"Overview of psychosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396515\">",
"    <span class=\"h3\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several over-the-counter, prescription, and illicit drugs can lead to weight loss (",
"    <a class=\"graphic graphic_table graphicRef69495 \" href=\"UTD.htm?8/61/9181\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97596818\">",
"    <span class=\"h4\">",
"     Over-the-counter medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many over-the-counter and herbal medications that can inadvertently cause patients to lose weight. A careful history is important in identifying nonprescription drug use (eg, nonsteroidal antiinflammatory drugs), herbal",
"    <span class=\"nowrap\">",
"     remedies/teas,",
"    </span>",
"    and food additives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97596867\">",
"    <span class=\"h4\">",
"     Prescription drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss is a known adverse effect of several common prescription drugs, including anticonvulsants, antidepressants, levodopa,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/47/21238?source=see_link\">",
"     liraglutide",
"    </a>",
"    , and thyroid medication.",
"   </p>",
"   <p>",
"    Marked weight loss can occur after reduction or withdrawal of some antipsychotic drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    , mesoridazine) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients who experience weight loss have usually been treated for many years with high doses. The rapid weight loss and ill appearance of cachexia due to antipsychotic drug withdrawal are quickly reversed, however, by resuming the original dose of antipsychotic medication. Weight loss with withdrawal of newer antipsychotic agents occurs infrequently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396522\">",
"    <span class=\"h4\">",
"     Substance abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss occurs commonly with several drugs of abuse:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many alcohol-dependent patients consume most of their calories from alcohol and thus have several nutritional deficiencies in addition to weight loss. However, weight loss in patients with alcoholic cirrhosis may be masked by secondary ascites and fluid retention.",
"     </li>",
"     <li>",
"      As many as 40 percent of chronic cocaine users experience weight loss, anorexia, and sleep disturbances. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=see_link\">",
"       \"Cocaine abuse and dependence in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Opiates directly inhibit the appetite center, decrease gastrointestinal motility, and can cause hyperalgesia with chronic abdominal pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3784?source=see_link&amp;anchor=H10#H10\">",
"       \"Opioid abuse and dependence: Overview and patient evaluation\", section on 'Other consequences'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Amphetamines promote release of catecholamines from presynaptic nerve terminals which can decrease appetite and increase basal metabolism.",
"     </li>",
"     <li>",
"      Withdrawal from chronic marijuana use can cause a syndrome that includes anorexia, weight loss, irritability, and strange dreams [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Heavy tobacco use leads to weight loss, whereas weight gain occurs with smoking cessation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396543\">",
"    <span class=\"h2\">",
"     Voluntary weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many persons lose weight voluntarily. Weight loss should be encouraged in overweight and obese patients who desire to lose weight, as long as there are no concerning symptoms or signs present. Evaluation and management of obesity are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=see_link\">",
"     \"Screening for and clinical evaluation of obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who are of normal weight or underweight, obsession with being overweight leads to weight loss as a result of decreased food intake, excessive exercise, self-induced vomiting,",
"    <span class=\"nowrap\">",
"     drug/herbal",
"    </span>",
"    medication use,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    behaviors suggestive of",
"    <span class=\"nowrap\">",
"     bulimia/anorexia",
"    </span>",
"    nervosa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with personality disorders and dependent tendencies may voluntarily decrease food intake or use other measures to lose weight as a mechanism for attention seeking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7512?source=see_link\">",
"     \"Factitious disorder and Munchausen syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, some persons have vocations that require them to be very lean (eg, long distance runners, models, ballet dancers, gymnasts). Some persons who engage in intense training must increase their intake of calories considerably to maintain their weight and muscle mass. Increased food intake is not always sufficient to maintain body weight, resulting in transient or persistent weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=see_link\">",
"     \"Exercise physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396550\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the broad differential diagnosis of involuntary weight loss (",
"    <a class=\"graphic graphic_table graphicRef69495 \" href=\"UTD.htm?8/61/9181\">",
"     table 1",
"    </a>",
"    ), there is no single diagnostic approach for all patients. The work-up should be individualized, based on findings from the patient's history and physical examination (",
"    <a class=\"graphic graphic_algorithm graphicRef58832 \" href=\"UTD.htm?36/32/37378\">",
"     algorithm 1",
"    </a>",
"    ). A standard evaluation of patients with unexplained weight loss will yield a diagnosis in the majority of cases (72 to 95 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/5,24,29,41-43\">",
"     5,24,29,41-43",
"    </a>",
"    ]. If no abnormality is identified after initial evaluation, the patient should be reassessed in one to six months. Currently, there are no widely-accepted guidelines for the clinical evaluation of weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396557\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Qualitative judgments by patients about the magnitude of their weight loss are often unreliable. In a prospective study of involuntary weight loss, only 50 percent of patients reporting weight loss had true weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/24\">",
"     24",
"    </a>",
"    ]. Therefore, in documenting weight loss, it is important to obtain previous weight records and, if not available, to query family members about the patient's weight history, including usual weight prior to the period of weight loss.",
"   </p>",
"   <p>",
"    As part of the history it is important to determine the duration and pattern of weight loss, including past fluctuations in weight and whether weight loss is progressive or stabilized. Weight loss in a person whose weight has been stable for many years and weight loss that is progressive are more worrisome and require more immediate follow-up. Other factors to consider include intention to lose weight, changes in appetite, caloric intake, and physical activity.",
"   </p>",
"   <p>",
"    Furthermore, the interviewing clinician should elicit medical, psychological, and functional factors associated with poor food intake. The nine D's associated with weight loss may help elicit these factors, particularly in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dentition",
"     </li>",
"     <li>",
"      Dysgeusia",
"     </li>",
"     <li>",
"      Dysphagia",
"     </li>",
"     <li>",
"      Diarrhea",
"     </li>",
"     <li>",
"      Depression",
"     </li>",
"     <li>",
"      Dementia",
"     </li>",
"     <li>",
"      Disease",
"     </li>",
"     <li>",
"      Dysfunction",
"     </li>",
"     <li>",
"      Drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A thorough review of systems is necessary if the etiology remains uncertain after the above questioning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396564\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several prospective studies have verified the importance of a complete physical examination in evaluating unexplained weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/24,42,45\">",
"     24,42,45",
"    </a>",
"    ]. The clinician should assess the overall appearance, affect, skin changes (eg, melanoma or spider angiomata), presence of lymphadenopathy, cardiopulmonary status, hepatosplenomegaly, abdominal mass,",
"    <span class=\"nowrap\">",
"     breast/prostate",
"    </span>",
"    abnormalities, rectal examination with stool hemoccult, and any neurologic deficit. In observational studies, abnormal physical findings were common among those with malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/25,42,45\">",
"     25,42,45",
"    </a>",
"    ]. As an example, in a prospective cohort study of 101 patients, 12 out of 22 patients (55 percent) diagnosed with cancer as the cause of weight loss had an abnormal physical examination finding [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/42\">",
"     42",
"    </a>",
"    ]. In another study, abnormal physical findings were found among 59 percent of patients who were diagnosed with either malignancy or other organic causes of weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/45\">",
"     45",
"    </a>",
"    ]. Conversely, abnormal physical findings were present in only 3 percent of those diagnosed with a psychiatric disorder or who remained undiagnosed after a thorough evaluation and follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396571\">",
"    <span class=\"h2\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with positive findings on history or physical examination, further testing should be focused on confirming the suspected diagnosis. When the history and physical examination do not indicate a likely diagnosis, a basic diagnostic evaluation should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory testing: complete blood count with differential, chemistries (electrolytes, glucose, calcium, renal and hepatic function, thyroid stimulating hormone), hemoglobin A1c, urinalysis, stool hemoccult, and erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) (",
"      <a class=\"graphic graphic_algorithm graphicRef58832 \" href=\"UTD.htm?36/32/37378\">",
"       algorithm 1",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      Diagnostic imaging: chest radiograph",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We do not recommend whole body CT scanning in the initial workup, although CT scanning may be indicated based on history or physical examination.",
"   </p>",
"   <p>",
"    Further studies should be based on results of these initial tests. Despite an appropriate initial evaluation, a clear cause for weight loss is often not found. Watchful waiting for one to six months is preferable to a battery of testing with low diagnostic yield. As organic disease is rarely found in patients with a normal physical examination and initial diagnostic testing, a waiting period of one to six months is unlikely to result in an adverse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/5,24,46\">",
"     5,24,46",
"    </a>",
"    ]. On follow-up, careful attention should be paid to dietary history, possibility of psychosocial causes, surreptitious drug intake, and new manifestations of occult illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H257481526\">",
"    <span class=\"h2\">",
"     Clinical prediction rules",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical prediction rules or standardized guidelines that have been externally validated or widely accepted for the clinical evaluation of weight loss. One clinical prediction rule to identify malignancy in patients with unexplained involuntary weight loss was prospectively validated at the same site in a group of 328 patients (in whom malignancy was identified in 35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/47\">",
"     47",
"    </a>",
"    ]. The independent predictors of malignancy included elevated levels of alkaline phosphatase and LDH, low albumin, leukocytosis, and advanced age (",
"    <a class=\"graphic graphic_table graphicRef69961 \" href=\"UTD.htm?23/56/24459\">",
"     table 2",
"    </a>",
"    ). This clinical prediction rule requires external validation prior to widespread use.",
"   </p>",
"   <p>",
"    In a prospective cohort study of 101 patients, 22 of 22 patients with malignancy had an abnormal laboratory test, with C-reactive protein, hemoglobin, lactate dehydrogenase, and albumin having the highest sensitivities [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2617/abstract/42\">",
"     42",
"    </a>",
"    ]. Abnormal abdominal ultrasound and chest radiograph had lower sensitivities, 45 and 18 percent, respectively.",
"    <strong>",
"    </strong>",
"    However, all of these diagnostic tests were also abnormal, but to a lesser extent, among patients with non-malignant organic disease. Thus, there is no general diagnostic test or group of tests that appears to be specific for malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H257481762\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of weight loss depends on the specific underlying cause. Treatment strategies include, but are not limited to, pharmacologic therapy (eg, infections, endocrinopathies),",
"    <span class=\"nowrap\">",
"     surgery/radiation",
"    </span>",
"    (eg, malignancy), behavioral therapy (eg, depression, anorexia nervosa), removal of offending agents (eg, ephedra, laxatives),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nutritional support (eg, dementia, dysphagia).",
"   </p>",
"   <p>",
"    Treatments for specific causes of weight loss are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=see_link\">",
"     \"Pharmacologic management of cancer anorexia/cachexia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42584?source=see_link\">",
"     \"Management of tissue wasting in patients with HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31946?source=see_link\">",
"     \"Geriatric nutrition: Nutritional issues in older adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42455?source=see_link\">",
"     \"Failure to thrive in elderly adults: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88396578\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinically-important weight loss is traditionally defined as loss of more than 5 percent of usual body weight over six months. (See",
"      <a class=\"local\" href=\"#H88396387\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are many causes of weight loss, which are classified as voluntary or involuntary (",
"      <a class=\"graphic graphic_table graphicRef69495 \" href=\"UTD.htm?8/61/9181\">",
"       table 1",
"      </a>",
"      ). Progressive involuntary weight loss often indicates serious medical or psychiatric illness. (See",
"      <a class=\"local\" href=\"#H88396429\">",
"       'Involuntary weight loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who are of normal weight or underweight, fear of weight gain can lead to weight loss through decreased food intake, excessive exercise, self-induced vomiting,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       drug/herbal",
"      </span>",
"      medication use. (See",
"      <a class=\"local\" href=\"#H88396543\">",
"       'Voluntary weight loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most large cohort studies have found that involuntary weight loss is associated with increased mortality. (See",
"      <a class=\"local\" href=\"#H88396401\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The work-up of a patient with weight loss should be individualized, based on findings from the patient's history and physical examination (",
"      <a class=\"graphic graphic_algorithm graphicRef58832 \" href=\"UTD.htm?36/32/37378\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H88396550\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the history and physical examination do not indicate a likely diagnosis, a basic diagnostic evaluation should include a complete blood count with differential, chemistries, hemoglobin A1c, urinalysis, stool hemoccult, erythrocyte sedimentation rate or C-reactive protein, and chest radiograph. Further studies should be based on results of these initial tests. If no abnormality is identified after initial evaluation, the patient should be reassessed in one to six months. (See",
"      <a class=\"local\" href=\"#H88396571\">",
"       'Diagnostic testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/1\">",
"      Bales CW, Ritchie CS. Sarcopenia, weight loss, and nutritional frailty in the elderly. Annu Rev Nutr 2002; 22:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/2\">",
"      Brinkworth GD, Noakes M, Buckley JD, Clifton PM. Weight loss improves heart rate recovery in overweight and obese men with features of the metabolic syndrome. Am Heart J 2006; 152:693.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Bistrian BR. Nutritional Assessment. In: Textbook of Medicine, Saunders, Philadelphia.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/4\">",
"      Meltzer AA, Everhart JE. Unintentional weight loss in the United States. Am J Epidemiol 1995; 142:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/5\">",
"      Bouras EP, Lange SM, Scolapio JS. Rational approach to patients with unintentional weight loss. Mayo Clin Proc 2001; 76:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/6\">",
"      Moriguti JC, Moriguti EK, Ferriolli E, et al. Involuntary weight loss in elderly individuals: assessment and treatment. Sao Paulo Med J 2001; 119:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/7\">",
"      Yaari S, Goldbourt U. Voluntary and involuntary weight loss: associations with long term mortality in 9,228 middle-aged and elderly men. Am J Epidemiol 1998; 148:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/8\">",
"      Sahyoun NR, Serdula MK, Galuska DA, et al. The epidemiology of recent involuntary weight loss in the United States population. J Nutr Health Aging 2004; 8:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/9\">",
"      Morley JE, Kraenzle D. Causes of weight loss in a community nursing home. J Am Geriatr Soc 1994; 42:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/10\">",
"      Murden RA, Ainslie NK. Recent weight loss is related to short-term mortality in nursing homes. J Gen Intern Med 1994; 9:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/11\">",
"      Flacker JM, Kiely DK. A practical approach to identifying mortality-related factors in established long-term care residents. J Am Geriatr Soc 1998; 46:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/12\">",
"      Flacker JM, Kiely DK. Mortality-related factors and 1-year survival in nursing home residents. J Am Geriatr Soc 2003; 51:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/13\">",
"      Wannamethee SG, Shaper AG, Lennon L. Reasons for intentional weight loss, unintentional weight loss, and mortality in older men. Arch Intern Med 2005; 165:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/14\">",
"      Gregg EW, Gerzoff RB, Thompson TJ, Williamson DF. Intentional weight loss and death in overweight and obese U.S. adults 35 years of age and older. Ann Intern Med 2003; 138:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/15\">",
"      Sj&ouml;str&ouml;m L, Narbro K, Sj&ouml;str&ouml;m CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/16\">",
"      Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/17\">",
"      Perry CD, Hutter MM, Smith DB, et al. Survival and changes in comorbidities after bariatric surgery. Ann Surg 2008; 247:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/18\">",
"      Hoogwerf BJ, Nuttall FQ. Long-term weight regulation in treated hyperthyroid and hypothyroid subjects. Am J Med 1984; 76:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/19\">",
"      Rodin GM, Daneman D. Eating disorders and IDDM. A problematic association. Diabetes Care 1992; 15:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/20\">",
"      Neal JM. Diabetic neuropathic cachexia: a rare manifestation of diabetic neuropathy. South Med J 2009; 102:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/21\">",
"      Blau RH. Diabetic neuropathic cachexia. Report of a woman with this syndrome and review of the literature. Arch Intern Med 1983; 143:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/22\">",
"      Bolland MJ, Grey AB, Gamble GD, Reid IR. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab 2005; 90:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/23\">",
"      Goldstein RE, O'Neill JA Jr, Holcomb GW 3rd, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999; 229:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/24\">",
"      Marton KI, Sox HC Jr, Krupp JR. Involuntary weight loss: diagnostic and prognostic significance. Ann Intern Med 1981; 95:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/25\">",
"      Rabinovitz M, Pitlik SD, Leifer M, et al. Unintentional weight loss. A retrospective analysis of 154 cases. Arch Intern Med 1986; 146:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/26\">",
"      Hern&aacute;ndez JL, Riancho JA, Matorras P, Gonz&aacute;lez-Mac&iacute;as J. Clinical evaluation for cancer in patients with involuntary weight loss without specific symptoms. Am J Med 2003; 114:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/27\">",
"      Lankisch P, Gerzmann M, Gerzmann JF, Lehnick D. Unintentional weight loss: diagnosis and prognosis. The first prospective follow-up study from a secondary referral centre. J Intern Med 2001; 249:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/28\">",
"      Staal-van den Brekel AJ, Schols AM, ten Velde GP, et al. Analysis of the energy balance in lung cancer patients. Cancer Res 1994; 54:6430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/29\">",
"      Vanderschueren S, Geens E, Knockaert D, Bobbaers H. The diagnostic spectrum of unintentional weight loss. Eur J Intern Med 2005; 16:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/30\">",
"      Grunfeld C, Feingold KR. Body weight as essential data in the management of patients with human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 1993; 58:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/31\">",
"      Grunfeld C. What causes wasting in AIDS? N Engl J Med 1995; 333:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/32\">",
"      Macallan DC, Noble C, Baldwin C, et al. Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 1995; 333:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/33\">",
"      Mij&aacute;n-de-la-Torre A. Recent insights on chronic heart failure, cachexia and nutrition. Curr Opin Clin Nutr Metab Care 2009; 12:251.",
"     </a>",
"    </li>",
"    <li>",
"     Schwartz DB, DiMaria RA. Pulmonary and Cardiac Failure [CD-ROM]. In: A.S.P.E.N. Nutrition Support Core Curriculum: A Case Based Approach-The Adult Patient, Gottschlich MM (Ed), 2007. p.492.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/35\">",
"      Shukla S, Hull R. Unintentional weight loss. Think of giant cell arteritis. BMJ 2011; 342:d2889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/36\">",
"      Thompson MP, Morris LK. Unexplained weight loss in the ambulatory elderly. J Am Geriatr Soc 1991; 39:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/37\">",
"      Huffman GB. Evaluating and treating unintentional weight loss in the elderly. Am Fam Physician 2002; 65:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/38\">",
"      Morley JE. Anorexia of aging: physiologic and pathologic. Am J Clin Nutr 1997; 66:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/39\">",
"      Mikkelsen EJ, Albert LG, Upadhyaya A. Neuroleptic-withdrawal cachexia. N Engl J Med 1988; 318:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/40\">",
"      Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004; 161:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/41\">",
"      Alibhai SM, Greenwood C, Payette H. An approach to the management of unintentional weight loss in elderly people. CMAJ 2005; 172:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/42\">",
"      Metalidis C, Knockaert DC, Bobbaers H, Vanderschueren S. Involuntary weight loss. Does a negative baseline evaluation provide adequate reassurance? Eur J Intern Med 2008; 19:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/43\">",
"      McMinn J, Steel C, Bowman A. Investigation and management of unintentional weight loss in older adults. BMJ 2011; 342:d1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/44\">",
"      Robbins LJ. Evaluation of weight loss in the elderly. Geriatrics 1989; 44:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/45\">",
"      Bilbao-Garay J, Barba R, Losa-Garc&iacute;a JE, et al. Assessing clinical probability of organic disease in patients with involuntary weight loss: a simple score. Eur J Intern Med 2002; 13:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/46\">",
"      Wise GR, Craig D. Evaluation of involuntary weight loss. Where do you start? Postgrad Med 1994; 95:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2617/abstract/47\">",
"      Hern&aacute;ndez JL, Matorras P, Riancho JA, Gonz&aacute;lez-Mac&iacute;as J. Involuntary weight loss without specific symptoms: a clinical prediction score for malignant neoplasm. QJM 2003; 96:649.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2770 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_35_2617=[""].join("\n");
var outline_f2_35_2617=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H88396578\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88396380\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88396387\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88396394\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88396401\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88396408\">",
"      Involuntary weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88396415\">",
"      Voluntary weight loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88396422\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88396429\">",
"      Involuntary weight loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88396437\">",
"      - Endocrinopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88396445\">",
"      Hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88396452\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88396459\">",
"      Other endocrine disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88396466\">",
"      - Gastrointestinal diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88396473\">",
"      - Malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88396480\">",
"      - HIV and other infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88396487\">",
"      - Advanced cardiac, pulmonary, and renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88396501\">",
"      - Neurologic diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H261330794\">",
"      - Systemic inflammatory disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88396508\">",
"      - Psychiatric disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88396515\">",
"      - Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H97596818\">",
"      Over-the-counter medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H97596867\">",
"      Prescription drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88396522\">",
"      Substance abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88396543\">",
"      Voluntary weight loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88396550\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88396557\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88396564\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88396571\">",
"      Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H257481526\">",
"      Clinical prediction rules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H257481762\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88396578\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2770\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2770|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?36/32/37378\" title=\"algorithm 1\">",
"      Evaluation of weight loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2770|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/61/9181\" title=\"table 1\">",
"      Major causes of weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/56/24459\" title=\"table 2\">",
"      Predictors of malignancy in weight loss",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=related_link\">",
"      Clinical features and pathogenesis of cancer cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=related_link\">",
"      Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=related_link\">",
"      Clinical manifestations of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20826?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=related_link\">",
"      Cocaine abuse and dependence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=related_link\">",
"      Epidemiology of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/12/14538?source=related_link\">",
"      Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=related_link\">",
"      Exercise physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7512?source=related_link\">",
"      Factitious disorder and Munchausen syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42455?source=related_link\">",
"      Failure to thrive in elderly adults: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31946?source=related_link\">",
"      Geriatric nutrition: Nutritional issues in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42584?source=related_link\">",
"      Management of tissue wasting in patients with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17610?source=related_link\">",
"      Medical complications of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/39/43639?source=related_link\">",
"      Nutritional support in advanced lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3784?source=related_link\">",
"      Opioid abuse and dependence: Overview and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=related_link\">",
"      Overview of psychosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=related_link\">",
"      Pharmacologic management of cancer anorexia/cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38233?source=related_link\">",
"      Poor weight gain in children older than two years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=related_link\">",
"      Risk factors for dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=related_link\">",
"      Screening for and clinical evaluation of obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/58/37799?source=related_link\">",
"      Superior mesenteric artery syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_35_2618="Antiplatelet therapy for secondary prevention of stroke";
var content_f2_35_2618=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Antiplatelet therapy for secondary prevention of stroke",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/35/2618/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/35/2618/contributors\">",
"     Brett L Cucchiara, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/35/2618/contributors\">",
"     Steven R Mess&eacute;, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/35/2618/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/35/2618/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/35/2618/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/35/2618/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/35/2618/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiplatelet therapy is used for both the management of acute ischemic stroke and for the prevention of stroke. Antiplatelet therapy reduces the incidence of stroke in patients at high risk for atherosclerosis and in those with known symptomatic cerebrovascular disease.",
"   </p>",
"   <p>",
"    Antiplatelet therapy for secondary stroke prevention will be reviewed here. Antiplatelet therapy for acute ischemic stroke and for primary stroke prevention is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31688?source=see_link\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prevention of recurrent stroke with antithrombotic therapy in patients with atrial fibrillation is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ASPIRIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    , the most commonly used antiplatelet agent, inhibits the enzyme cyclooxygenase, reducing production of thromboxane A2, a stimulator of platelet aggregation. This interferes with the formation of thrombi, thereby reducing the risk of stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for preventing ischemic stroke and cardiovascular events is supported by a meta-analysis from the Antithrombotic Trialists Collaboration (ATC) published in 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/1\">",
"     1",
"    </a>",
"    ]. The ATC analyzed 195 randomized controlled trials comparing antiplatelet therapy, primarily aspirin, with placebo in the prevention of stroke, myocardial infarction (MI), and vascular death among high-risk patients with some vascular disease or other condition implying an increased risk of occlusive vascular disease. Patients treated with an antiplatelet agent (primarily aspirin) had a 25 percent relative risk reduction in nonfatal stroke compared with placebo.",
"   </p>",
"   <p>",
"    Among the subset of patients in the 2002 ATC with prior cerebrovascular disease (TIA or stroke), antiplatelet therapy reduced the risk of secondary stroke, MI, or vascular death by 22 percent; the absolute benefit was 36 events prevented per 1000 patients treated for 29 months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/1\">",
"     1",
"    </a>",
"    ]. The benefit of antiplatelet therapy was independent of sex, age (greater or less than 65), diabetes, or hypertension. Similar results were reported in a 2009 ATC meta-analysis of 16 placebo-controlled secondary prevention trials;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    reduced the risk of any serious vascular event by 19 percent and reduced the risk of ischemic stroke by 22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stopping antiplatelet therapy in high-risk patients may itself increase the risk of stroke. One study found that 13 of 289 patients hospitalized with cerebral infarction had recently stopped antiplatelet therapy; most had been taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/3\">",
"     3",
"    </a>",
"    ]. In all 13, the antiplatelet agent had been discontinued within 6 to 10 days of stroke onset, a time course consistent with the known lifespan (about 10 days) of inhibited platelets. Additionally, a case-control study comparing 309 patients with stroke to 309 matched controls found that discontinuation of aspirin was associated with a significantly increased risk of TIA or ischemic stroke (odds ratio 3.4, 95% CI 1.08-10.63) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to its benefit for secondary stroke prevention, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    decreases the risk of other cardiovascular events in a wide range of patients with established disease. Furthermore, there is considerable evidence that long-term aspirin use reduces the risk of death from certain cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42378?source=see_link&amp;anchor=H35#H35\">",
"     \"Cancer prevention\", section on 'Aspirin and other anti-inflammatory drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The issues of nonresponse and resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and the effect of enteric coating on antiplatelet activity, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19401?source=see_link\">",
"     \"Nonresponse and resistance to aspirin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies evaluating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    treatment and aspirin doses for patients undergoing carotid endarterectomy are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=see_link&amp;anchor=H93838520#H93838520\">",
"     \"Carotid endarterectomy\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dose of aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in secondary stroke prevention studies ranged between 20 to 1300 mg. Most studies have found that 50 to 325",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of aspirin is as effective as higher doses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/1,5-10\">",
"     1,5-10",
"    </a>",
"    ]. Furthermore, lower doses within this range appear to provide the same benefit as higher doses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/1,6,10\">",
"     1,6,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a review of 195 trials of secondary prevention by the ATC showed that doses of 75 to 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    produced the same risk reduction, compared with placebo, as doses of 150 to 325",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/1\">",
"     1",
"    </a>",
"    ]. In the ATC analysis of trials directly comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    &lt;75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    to aspirin &ge;75",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    there was no significant difference in effectiveness between the two regimens. However, the ATC noted that aspirin doses of &lt;75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    have been less widely assessed than doses of 75 to 150",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    so uncertainty remains regarding the effectiveness of doses &lt;75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    compared with higher aspirin doses.",
"   </p>",
"   <p>",
"    Even lower doses may be effective, as demonstrated in the Dutch TIA Trial [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/11\">",
"     11",
"    </a>",
"    ]. This study found similar efficacy for stroke prevention with 30 mg compared with 283 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    per day in patients who had had a TIA or minor ischemic stroke. In the European Stroke Prevention Study-2 (ESPS-2), 50 mg of aspirin daily reduced stroke risk by 18 percent compared with placebo (29 strokes prevented per 1000 treated), an effect of comparable magnitude to the other trials cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/6\">",
"     6",
"    </a>",
"    ]. This benefit seen with very low-dose aspirin is consistent with laboratory observations that 30 mg of aspirin per day results in complete suppression of thromboxane A2 production [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the apparent equivalent benefit of different doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for ischemic stroke prevention, and the increased risk of bleeding complications with higher dose aspirin discussed below, we recommend a dose of 50 to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    when using aspirin for the secondary prevention of ischemic stroke. This recommendation is similar to the dose of 75 to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    recommended by current guidelines from the American College of Chest Physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Toxicity and risk of bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    appear to be associated with less gastrointestinal toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/5,11,14\">",
"     5,11,14",
"    </a>",
"    ]. In the UK TIA trial, for example, gastrointestinal hemorrhage occurred in 1.6 percent of patients on placebo, 2.6 percent on 300 mg aspirin, and 4.7 percent on 1200 mg aspirin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/5\">",
"     5",
"    </a>",
"    ]. A similar dose relationship was seen for milder gastrointestinal symptoms.",
"   </p>",
"   <p>",
"    In an analysis of data from 31 randomized, controlled trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    doses &le;200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    were associated with a significantly lower rate of major bleeding events compared with higher doses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/15\">",
"     15",
"    </a>",
"    ]. However, there was no difference in major bleeding when aspirin &lt;100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was compared with 100 to 200",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    When the overall rate of bleeding complications (including major, minor and insignificant events) was considered, aspirin &lt;100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was associated with a lower risk compared with the 100 to 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and &gt;200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    groups",
"   </p>",
"   <p>",
"    A later meta-analysis of 22 randomized trials of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75 to 325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    versus placebo for cardiovascular prophylaxis reached similar conclusions within the low-dose range [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/16\">",
"     16",
"    </a>",
"    ]. Compared with placebo, aspirin increased the relative risk of any major bleeding, major gastrointestinal bleeding, and intracranial bleeding by 1.7- to 2.1-fold. However, the absolute annual increase in risk for any major bleeding episode (mostly gastrointestinal) and for intracranial bleeding was 0.13 and 0.03 percent, respectively. Furthermore, there was no evidence of an increased risk of bleeding with \"high\" low-dose aspirin (&gt;162 to 325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    compared with \"low\" low-dose aspirin (75 to 162",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLOPIDOGREL",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     Clopidogrel",
"    </a>",
"    is a thienopyridine that inhibits ADP-dependent platelet aggregation.",
"   </p>",
"   <p>",
"    The CAPRIE trial randomly assigned 19,185 patients with recent stroke, MI, or symptomatic peripheral artery disease (divided roughly equally between these three enrolling diseases) to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (325 mg) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (75 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/17\">",
"     17",
"    </a>",
"    ]. The primary end point, a composite outcome of stroke, MI, or vascular death, was significantly reduced with clopidogrel treatment compared with aspirin treatment (5.3 versus 5.8 percent annually, relative risk reduction 8.7 percent, 95% CI 0.3-16.5 percent).",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in the CAPRIE trial varied based on enrolling disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/17\">",
"     17",
"    </a>",
"    ]. Most of the benefit was observed in patients with peripheral artery disease, and the difference in composite outcome between clopidogrel and aspirin treatment in patients with recent stroke and myocardial infarction was not significant. However, the strength of these observations is limited, since they are based on subgroup analyses.",
"   </p>",
"   <p>",
"    Polymorphisms in the hepatic enzymes involved in the metabolism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (eg, CYP1A2, CYP3A4, CYP2C19) or within the platelet P2Y12 receptor may affect the ability of clopidogrel to inhibit platelet aggregation. However, there are no convincing prospective data to support routine testing for clopidogrel resistance with in vitro tests of platelet function or genotyping in patients with cardiovascular disease, particularly for those with a history of stroke or TIA. A 2010 clinical alert from the American College of Cardiology Foundation and the American Heart Association noted that adherence to existing guidelines for the use of antiplatelet therapy should remain the basis for therapy, and further that there is insufficient evidence to recommend routine platelet function testing or genetic testing for clopidogrel [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The issue of",
"    <span class=\"nowrap\">",
"     resistance/nonresponse",
"    </span>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in cardiovascular disease is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link\">",
"     \"Nonresponse and resistance to clopidogrel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Side effects of clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effect profile of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is favorable compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , with a slightly higher frequency of rash and diarrhea, but a slightly lower frequency of gastric upset or gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/16\">",
"     16",
"    </a>",
"    ]. Unlike its close relative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Ticlopidine'",
"    </a>",
"    below), severe neutropenia is not seen more frequently with clopidogrel than with aspirin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Aspirin plus clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with ischemic stroke, the combined long-term use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    does not offer greater benefit for stroke prevention than either agent alone but does substantially increase the risk of bleeding complications [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This conclusion is supported by results from the MATCH trial [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/19\">",
"     19",
"    </a>",
"    ]. This study enrolled 7599 patients with stroke or TIA who also had some additional \"high-risk\" feature, defined as prior MI, prior stroke (in addition to the index event), diabetes, angina, or symptomatic peripheral artery disease (PAD). The primary end point was a composite of ischemic stroke, MI, vascular death, or rehospitalization for acute ischemia. Patients were randomly assigned to the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (75 mg daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75 mg daily) versus clopidogrel (75 mg daily) alone. Follow-up was 18 months. The following observations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      treatment did not reduce the risk of major vascular events compared with clopidogrel alone (relative risk reduction 6.4 percent, 95% CI -4.6 to 16.3 percent).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      was associated with a significant increase in life-threatening bleeding complications, mainly intracranial and gastrointestinal, compared with clopidogrel alone. Over the 18-month trial period, there was an absolute excess of 1.3 percent for life-threatening hemorrhage (95% CI 0.6-1.9) and an additional 1.3 percent for major hemorrhage in patients assigned combination therapy.",
"     </li>",
"     <li>",
"      Overall, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      compared with clopidogrel alone might prevent 10 ischemic events per 1000 treated (not statistically significant) at the cost of 13 life-threatening hemorrhages per 1000 treated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several authors have noted limitations of MATCH. For instance, 54 percent of MATCH subjects qualified for trial entry because of a lacunar stroke, a stroke subtype that has the lowest recurrence risk [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/22\">",
"     22",
"    </a>",
"    ]. Furthermore, data regarding interaction between treatment and stroke mechanism were not reported, raising the question of whether combination therapy might still play a role in particular stroke subtypes. (See",
"    <a class=\"local\" href=\"#H640139\">",
"     'Stroke subtypes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    has been shown to have benefit over aspirin alone in patients with acute coronary syndromes. However, there are important differences between patients with coronary and cerebrovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/23\">",
"     23",
"    </a>",
"    ], and between short-term therapy initiated in the acute setting, and longer term preventative therapy. The results of the MATCH trial serve to emphasize these differences. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H16#H16\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Clopidogrel'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the MATCH trial [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/19\">",
"     19",
"    </a>",
"    ], which evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    versus",
"    <strong>",
"     clopidogrel",
"    </strong>",
"    alone in patients with stroke or TIA, the CHARISMA trial evaluated aspirin plus clopidogrel versus",
"    <strong>",
"     aspirin",
"    </strong>",
"    alone in 15,603 patients with either documented cardiovascular disease (coronary, ischemic cerebrovascular, or peripheral arterial) or, in 21 percent of patients, multiple atherothrombotic risk factors (eg, diabetes, hypertension, primary hypercholesterolemia, current smoking, asymptomatic carotid stenosis &ge;70 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients were randomly assigned to low-dose aspirin (75 to 162",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus either clopidogrel (75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo. The following observations were reported at a median of 28 months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combined",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      treatment did not reduce the risk of the composite primary end point (MI, stroke of any cause, or death from cardiovascular causes) compared with aspirin alone (6.8 versus 7.3 percent, relative risk [RR] 0.93, 95% CI 0.83-1.05)",
"     </li>",
"     <li>",
"      Combination therapy compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      alone was associated with a significant increase in moderate bleeding (2.1 versus 1.3 percent) and a nonsignificant increase in severe bleeding (1.7 versus 1.3 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H640139\">",
"    <span class=\"h3\">",
"     Stroke subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of dual antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    has been studied in different subtypes of ischemic stroke, including small vessel disease and large artery atherosclerosis.",
"   </p>",
"   <p>",
"    In a randomized trial (SPS3) evaluating over 3000 patients with subcortical (ie, lacunar) stroke confirmed by MRI, the arm testing the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    versus aspirin alone was terminated before completion because of a higher frequency of bleeding events (mostly systemic) and a higher mortality rate in patients assigned to dual antiplatelet therapy compared with those assigned to aspirin only [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/24\">",
"     24",
"    </a>",
"    ]. In the final analysis, subjects treated with aspirin plus clopidogrel compared with aspirin alone had a significantly increased annual rate of both major hemorrhage (2.1 versus 1.1 percent, hazard ratio [HR] 1.97, 95% CI 1.41-2.71) and all-cause mortality (2.1 versus 1.4 percent, HR 1.52, 95% CI 1.14-2.04) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/25\">",
"     25",
"    </a>",
"    ]. These results, particularly when interpreted together with those of the MATCH trial (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Aspirin plus clopidogrel'",
"    </a>",
"    above), suggest that dual antiplatelet therapy with aspirin and clopidogrel is harmful for long-term use in patients with lacunar stroke. Furthermore, treatment with aspirin and clopidogrel compared with aspirin alone in the SPS3 trial did not reduce the risk of recurrent stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two small trials (CARESS and CLAIR) of patients with recently symptomatic large artery stenosis found that, compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone, early treatment with aspirin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    reduced the number of microembolic signals detected on transcranial Doppler ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, whether this surrogate measure would translate into clinical benefit for patients with symptomatic large artery stenosis remains uncertain.",
"   </p>",
"   <p>",
"    In the SAMMPRIS trial, which evaluated angioplasty and stenting plus intensive medical management versus intensive medical management alone for patients with recently symptomatic intracranial large artery stenosis, all subjects received combined",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    for the first 90 days after enrollment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/28\">",
"     28",
"    </a>",
"    ]. The results were notable for a reduced rate of recurrent stroke and death in the medical management arm compared with historical controls, suggesting that short-term dual antiplatelet therapy is beneficial in this scenario. Therefore, we suggest dual antiplatelet therapy with aspirin plus clopidogrel for 90 days, followed by antiplatelet monotherapy, for patients with recently symptomatic intracranial large artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2010?source=see_link&amp;anchor=H87797058#H87797058\">",
"     \"Intracranial large artery atherosclerosis\", section on 'SAMMPRIS trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of antiplatelets in the acute phase (the first 48 hours) of ischemic stroke is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31688?source=see_link&amp;anchor=H2#H2\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\", section on 'Antiplatelet agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    to prevent recurrent stroke in patients with atrial fibrillation is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H19#H19\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Aspirin plus clopidogrel'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIPYRIDAMOLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     Dipyridamole",
"    </a>",
"    impairs platelet function by inhibiting the activity of adenosine deaminase and phosphodiesterase, which causes an accumulation of adenosine, adenine nucleotides, and cyclic AMP. Dipyridamole may also cause vasodilation.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     Dipyridamole",
"    </a>",
"    is currently available in two forms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An immediate-release form, usually given as 50 to 100 mg three times per day",
"     </li>",
"     <li>",
"      A proprietary formulation containing both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (25 mg) plus extended-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      (200 mg), given two times per day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    monotherapy for secondary stroke prevention was established by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ESPS-2 trial randomly assigned 6602 patients with a recent transient ischemic attack (TIA) or ischemic stroke to one of four groups: 200 mg extended-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      alone given twice daily; 25 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      alone given twice daily; a combination of 25 mg aspirin plus 200 mg extended-release dipyridamole given twice daily; and placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/6\">",
"       6",
"      </a>",
"      ]. An independent and significant benefit for stroke risk reduction was observed for both extended-release dipyridamole monotherapy (odds ratio [OR] 0.81, 95% CI 0.76-0.99) and aspirin monotherapy (OR 0.79, 95% CI 0.65-0.97) compared with placebo. The benefit of combination",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"       aspirin-extended-release dipyridamole",
"      </a>",
"      was significantly greater still than the two components alone (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Aspirin plus dipyridamole'",
"      </a>",
"      below) and significantly greater than placebo (OR 0.59, 95% CI 0.48-0.73).",
"     </li>",
"     <li>",
"      A subsequent meta-analysis of individual patient data from all available randomized trials found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      alone was effective for reducing recurrent stroke compared with control (odds ratio (OR) 0.82, 95% CI 0.68-1.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/29\">",
"       29",
"      </a>",
"      ]. Since the ESPS-2 trial [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/6\">",
"       6",
"      </a>",
"      ] provided 57 percent of the data in this meta-analysis, it is possible that ESPS-2 was the primary driver behind the results [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/29\">",
"       29",
"      </a>",
"      ]. When ESPS-2 data were excluded, the effectiveness of dipyridamole alone compared with control did not achieve statistical significance. Whether this is related to the lower doses and immediate-release formulation used in trials other than ESPS-2 remains unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Side effects of dipyridamole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache is a well known side effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/29\">",
"     29",
"    </a>",
"    ], and was the most frequent adverse event associated with extended-release dipyridamole in two large clinical trials, ESPS-2 and ESPRIT [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/6,30\">",
"     6,30",
"    </a>",
"    ]. In a study of subjects aged 55 or older treated with the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"     aspirin-extended-release dipyridamole",
"    </a>",
"    , headache developed in 39.7 percent after a single dose, and women were significantly more likely to develop headache than men (49.6 and 28.6 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/31\">",
"     31",
"    </a>",
"    ]. The headaches associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -extended-release dipyridamole treatment were mostly self-limited, and treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    was not significantly better than with placebo, as measured by response at two hours (75.5 and 69.4 percent). The overall incidence of headache declined markedly over seven days to less than 20 percent. Gastric upset",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea requiring drug cessation was also more common with dipyridamole compared with aspirin or placebo in ESPS-2.",
"   </p>",
"   <p>",
"    Notably,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use was associated with significantly greater overall bleeding and gastrointestinal bleeding compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    or placebo in ESPS-2 and a subsequent meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/6,29\">",
"     6,29",
"    </a>",
"    ]. In fact, in ESPS-2, the frequency of bleeding complications with dipyridamole was comparable to placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cardiac effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concern that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    use might lead to increased rates of myocardial ischemia has been largely laid to rest by data from two large clinical trials (ESPS-2 and ESPRIT) and a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/29,30,32\">",
"     29,30,32",
"    </a>",
"    ]. This concern is related to the potential for dipyridamole to cause vasodilation of coronary vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/33\">",
"     33",
"    </a>",
"    ], and it first arose with the use of intravenous dipyridamole in cardiac stress testing [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/34\">",
"     34",
"    </a>",
"    ]. Because of this issue, the 2002 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association guideline for the management of patients with chronic stable angina recommend avoidance of dipyridamole in patients with stable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the following observations suggest that extended-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    use for stroke prevention is NOT associated with an increased risk of myocardial ischemia or infarction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of data from ESPS-2 found that use of extended-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      was not associated with increased cardiac ischemia or mortality in patients with a history of coronary artery disease [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis found that oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      had a neutral cardiac effect and did not alter the rate of myocardial infarction (MI) in patients with previous stroke or TIA, either when compared with control, or when administered in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and compared with aspirin alone [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In ESPRIT, the use of combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      , mainly extended-release dipyridamole, was associated with a nonsignificant decrease in the outcome of first cardiac event, and a significant decrease in the primary composite outcome that included death from all vascular causes and nonfatal MI [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Aspirin plus dipyridamole'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Aspirin plus dipyridamole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beneficial effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    for secondary stroke prevention appear to be additive such that the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"     aspirin-extended-release dipyridamole",
"    </a>",
"    is significantly more effective than aspirin alone for stroke prevention. The data supporting this conclusion come from the following randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of six randomized trials with 7648 patients, stroke risk was significantly reduced with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      (including immediate and extended-release formulations) compared with aspirin alone (relative risk 0.77, 95% CI 0.67-0.89) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/36\">",
"       36",
"      </a>",
"      ]. Nearly 80 percent of the patients in this meta-analysis came from just two trials, ESPS-2 and ESPRIT.",
"     </li>",
"     <li>",
"      In the ESPS-2 trial, the stroke rate at 24 months of follow-up was significantly reduced in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"       aspirin-extended-release dipyridamole",
"      </a>",
"      group compared with the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      alone group (9.9 versus 12.9 percent; relative risk reduction 23 percent, 95% CI 9.2-37.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/6\">",
"       6",
"      </a>",
"      ]. There was no significant difference in the risk of death between the two groups. The risk of bleeding complications was not significantly different between the aspirin-extended-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      group and the aspirin monotherapy group, whereas both groups experienced a greater frequency of bleeding complications than the placebo group.",
"     </li>",
"     <li>",
"      In the later ESPRIT trial, 2739 patients within six months of a transient ischemic attack or minor stroke of presumed arterial origin were randomly assigned to open-label treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (30 to 325",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      alone or aspirin plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      (200 mg twice daily). The median aspirin dose was 75",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in both treatment groups, and the dipyridamole formulation used by most patients (83 percent) was extended release rather than immediate release [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/30\">",
"       30",
"      </a>",
"      ]. Over a mean follow-up of 3.5 years, the composite primary outcome (death from all vascular causes, nonfatal stroke, nonfatal myocardial infarction (MI), or major bleeding complication) was significantly less frequent in the aspirin plus dipyridamole group than the aspirin group (13 versus 16 percent, hazard ratio 0.80, 95% CI 0.66-0.98, absolute risk reduction 1.0 percent per year).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ESPRIT included patients using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    doses ranging from 30 to 325 mg daily, allaying concerns that the very low aspirin dose (25 mg twice daily) used in ESPS-2 was in part responsible for the benefit of combined",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"     aspirin-extended-release dipyridamole",
"    </a>",
"    over aspirin alone.",
"   </p>",
"   <p>",
"    The specific",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    preparation may be important. In the meta-analysis cited above, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and immediate-release dipyridamole was nonsignificantly better than aspirin alone for secondary prevention of stroke (RR 0.83, 95% CI 0.59-1.15) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/36\">",
"     36",
"    </a>",
"    ]. In contrast, extended release dipyridamole was used in all or the vast majority of patients in the much larger ESPS-2 and ESPRIT trials [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/6,30\">",
"     6,30",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"     aspirin-extended-release dipyridamole",
"    </a>",
"    was associated with a significant reduction in stroke risk compared with aspirin alone (RR 0.76, 95% CI 0.65-0.89) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Headache is the most common side effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Side effects of dipyridamole'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There has been concern that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    might induce coronary ischemia by a coronary steal phenomenon caused by vasodilation. Although the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"     aspirin-extended-release dipyridamole",
"    </a>",
"    does not provide additional benefit over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone for reducing MI, neither ESPS-2 nor ESPRIT found an increase in risk [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/6,30\">",
"     6,30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Cardiac effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Aspirin plus extended-release dipyridamole versus clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PRoFESS trial showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    monotherapy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"     aspirin-extended-release dipyridamole",
"    </a>",
"    have similar risks and benefits for secondary stroke prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/37\">",
"     37",
"    </a>",
"    ]. The trial enrolled 20,332 patients with noncardioembolic ischemic stroke and randomly assigned them to treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -extended-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    <span class=\"nowrap\">",
"     (25/200",
"    </span>",
"    mg twice daily) or clopidogrel (75 mg once daily). PRoFESS had a 2x2 factorial design in which the patients were also randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/38/27239?source=see_link\">",
"     telmisartan",
"    </a>",
"    or placebo, the results of which are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=see_link&amp;anchor=H5#H5\">",
"     \"Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack\", section on 'PRoFESS trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At an average follow-up of 2.5 years, the following observations were noted with antiplatelet therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no difference between treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"       aspirin-extended-release dipyridamole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      for the primary outcome of recurrent stroke (9.0 versus 8.8 percent, hazard ratio [HR] 1.01, 95% CI 0.92-1.11).",
"     </li>",
"     <li>",
"      There was no treatment difference between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"       aspirin-extended-release dipyridamole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      for the composite secondary outcome of stroke, myocardial infarction, or vascular death (13.1 versus 13.1 percent, HR 0.99, 95% CI 0.92-1.07).",
"     </li>",
"     <li>",
"      Despite the nearly identical event rates for both the primary and secondary outcomes, the trial failed to meet the prespecified noninferiority criteria for treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"       aspirin-extended-release dipyridamole",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Among patients who had recurrent strokes, the rate of recurrent ischemic stroke was slightly lower in those assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"       aspirin-extended-release dipyridamole",
"      </a>",
"      compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (7.7 vs 7.9 percent), but hemorrhagic strokes were slightly increased (0.9 vs 0.5 percent). The benefit-risk ratio, expressed as the combination of recurrent stroke plus major hemorrhage, was not significantly different between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      -extended-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      and clopidogrel (11.7 versus 11.4 percent; HR 1.03, 95% CI 0.95-1.11).",
"     </li>",
"     <li>",
"      New or worsening heart failure was slightly less frequent in patients assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"       aspirin-extended-release dipyridamole",
"      </a>",
"      compared to those assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ; the difference was significant (1.4 versus 1.8 percent, 95% CI 0.62-0.96).",
"     </li>",
"     <li>",
"      Discontinuation due to headache was significantly more frequent in patients assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"       aspirin-extended-release dipyridamole",
"      </a>",
"      than in those assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (5.9 versus 0.9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OTHER AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ticlopidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     Ticlopidine",
"    </a>",
"    is a thienopyridine with a chemical structure and mechanism of action similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . Its role in stroke prevention has been evaluated in three major trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CATS trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      with placebo in patients who had suffered a significant stroke. At a mean of 24 months follow-up, the primary composite end point of stroke, myocardial infarction (MI), and vascular death was significantly lower with ticlopidine compared with placebo (10.8 versus 15.3 percent, relative risk reduction 30 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/38\">",
"       38",
"      </a>",
"      ]. Analysis by intention-to-treat gave a smaller estimate of relative risk reduction for stroke, MI, or vascular death (23 percent).",
"     </li>",
"     <li>",
"      The TASS trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      (500",
"      <span class=\"nowrap\">",
"       mg/d)",
"      </span>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (1300",
"      <span class=\"nowrap\">",
"       mg/d)",
"      </span>",
"      in 3069 patients with a recent transient ischemic attack (TIA) or mild stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/39\">",
"       39",
"      </a>",
"      ]. At three-year follow-up, ticlopidine was associated with a significant reduction in the primary end point (nonfatal stroke or death) compared with aspirin (17 versus 19 percent). Ticlopidine treatment was also associated with a significant reduction in the rate of fatal and nonfatal stroke compared with aspirin (10 versus 13 percent, respectively; relative risk reduction 21 percent [95% CI, 4 - 38]).",
"     </li>",
"     <li>",
"      The AAASPS trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      (500",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (650",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      in 1809 black patients with noncardioembolic ischemic stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/40\">",
"       40",
"      </a>",
"      ]. At two-year follow-up, there was no significant difference in the primary end point (stroke, MI, vascular death) between ticlopidine and aspirin. However, for the end point of fatal or non-fatal stroke, there was a trend favoring aspirin over ticlopidine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the evidence of benefit in the CATS and TASS trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    is generally not considered a first-line antiplatelet agent for stroke prevention because of side effects and relatively high cost. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Choosing initial therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Side effects of ticlopidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most serious complication of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    therapy is severe neutropenia, which occurs in approximately 1 percent of patients. Thus, for the first three months of treatment, patients must undergo biweekly complete blood counts. This side effect limits the utility of ticlopidine. Other common side effects, which occur more frequently with ticlopidine than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , are rash and diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105978174\">",
"    <span class=\"h2\">",
"     Cilostazol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiplatelet agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38502?source=see_link\">",
"     cilostazol",
"    </a>",
"    is a phosphodiesterase 3 inhibitor that is used mainly for intermittent claudication in patients with peripheral artery disease. Several controlled trials have found that cilostazol is effective for preventing cerebral infarction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the CSPS trial of over 1000 patients from Japan,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38502?source=see_link\">",
"       cilostazol",
"      </a>",
"      (100 mg twice daily) compared with placebo significantly reduced the risk of stroke (relative risk reduction 42 percent, 95% CI 9.2-62.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the CASISP trial from China of 720 patients with recent ischemic stroke, the composite endpoint (any stroke, ischemic or hemorrhagic) at 12 to 18 months of follow-up was lower in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38502?source=see_link\">",
"       cilostazol",
"      </a>",
"      group compared with the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      group (3.3 versus 5.6 percent, hazard ratio [HR] 0.62, 95% CI 0.30-1.26) but this result was not statistically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the non-inferiority CSPS II trial, 2757 patients in Japan with a recent noncardioembolic cerebral infarction were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38502?source=see_link\">",
"       cilostazol",
"      </a>",
"      (100 mg twice daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (81 mg daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/43\">",
"       43",
"      </a>",
"      ]. At a mean follow-up of 29 months, the yearly rates of recurrent stroke (infarction or hemorrhage) for cilostazol and aspirin were 2.7 and 3.7 percent (HR 0.74, 95% CI 0.56-0.98), confirming that cilostazol is non-inferior to aspirin for stroke prevention. Annual rates of hemorrhagic events (intracerebral hemorrhage, subarachnoid hemorrhage, or other hemorrhage requiring hospitalization) were lower with cilostazol than with aspirin (0.8 versus 1.8 percent, HR 0.46, 95% CI 0.30-0.71). However, headache, diarrhea, palpitation, dizziness, and tachycardia were more frequent with cilostazol, and more patients discontinued cilostazol than aspirin (20 versus 12 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data support the safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38502?source=see_link\">",
"     cilostazol",
"    </a>",
"    for secondary stroke prevention in Asian populations. However, there are as yet no high-quality data regarding the use of cilostazol for secondary stroke prevention in non-Asian ethnic groups. Also, the lower tolerability and higher cost of cilostazol compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may limit its more widespread use for stroke prevention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Triflusal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triflusal is an antiplatelet agent that is structurally related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . It is available as a licensed pharmaceutical in some European and Latin American countries, but is considered investigational in the United States.",
"   </p>",
"   <p>",
"    In a randomized trial with 2113 patients, the effectiveness of triflusal was similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    at preventing vascular events after stroke, but it did have a lower rate of hemorrhagic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/44\">",
"     44",
"    </a>",
"    ]. Similar findings were noted in a smaller randomized trial and a meta-analysis of four trials [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. It is not clear whether triflusal would have had a lower rate of hemorrhagic complications than lower-dose aspirin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CHOOSING INITIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    is effective for secondary stroke prevention in patients with noncardioembolic TIA and ischemic stroke. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    treatment was better than aspirin as measured by a composite outcome of stroke, MI, or vascular death in the CAPRIE study [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/17\">",
"     17",
"    </a>",
"    ], and the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"     aspirin-extended-release dipyridamole",
"    </a>",
"    had greater benefit for secondary stroke risk reduction than aspirin alone in two clinical trials (ESPS-2 and ESPRIT) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/6,30\">",
"     6,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current guidelines from the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association",
"    <span class=\"nowrap\">",
"     (AHA/ASA)",
"    </span>",
"    and the American College of Chest Physicians (ACCP) recommend that patients with a noncardioembolic (ie, atherothrombotic, lacunar, or cryptogenic) stroke or TIA and no contraindication receive an antiplatelet agent to reduce the risk of recurrent stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/13,48\">",
"     13,48",
"    </a>",
"    ]. These guidelines note that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , and the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"     aspirin-extended-release dipyridamole",
"    </a>",
"    are all acceptable options for preventing recurrent noncardioembolic ischemic stroke or TIA. The 2012 ACCP guidelines include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38502?source=see_link\">",
"     cilostazol",
"    </a>",
"    in this group of recommended antiplatelet agents, and further suggest the use of the combination of aspirin-extended-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    or clopidogrel over aspirin or cilostazol [",
"    <a class=\"abstract\" href=\"UTD.htm?2/35/2618/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the available data, we suggest treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    75 mg daily as monotherapy, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"     aspirin-extended-release dipyridamole",
"    </a>",
"    25",
"    <span class=\"nowrap\">",
"     mg/200",
"    </span>",
"    mg twice a day, rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone. Some experts still prefer aspirin as the first-line agent, noting that the alternative antiplatelet regimens (clopidogrel or aspirin-extended-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    ) have an apparent modest advantage in benefit that is potentially offset by a disadvantage in cost.",
"   </p>",
"   <p>",
"    Immediate-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    cannot be routinely recommended for secondary prevention of ischemic stroke, given the limited evidence supporting its effectiveness and the significant pharmacokinetic differences between it and extended-release dipyridamole.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     Ticlopidine",
"    </a>",
"    is rarely used because of its side-effect profile and lack of clear superiority over the other available agents.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    should not be used in combination for stroke prevention, given the lack of greater efficacy compared with either agent alone, and given the substantially increased risk of bleeding complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       \"Patient information: Stroke (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/37/36435?source=see_link\">",
"       \"Patient information: Medicines after an ischemic stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/18/20772?source=see_link\">",
"       \"Patient information: Transient ischemic attack (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/53/19286?source=see_link\">",
"       \"Patient information: Ischemic stroke treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , and the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"       aspirin-extended-release dipyridamole",
"      </a>",
"      are all acceptable options for preventing recurrent noncardioembolic ischemic stroke.",
"     </li>",
"     <li>",
"      For patients with a history of noncardioembolic stroke or transient ischemic attack (TIA) of atherothrombotic, lacunar (small vessel occlusive type), or cryptogenic type, we recommend treatment with an antiplatelet agent (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest initial antiplatelet therapy using either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (75 mg daily) as monotherapy, or the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"       aspirin-extended-release dipyridamole",
"      </a>",
"      (25",
"      <span class=\"nowrap\">",
"       mg/200",
"      </span>",
"      mg twice a day), rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). The choice between clopidogrel and aspirin-extended-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      is dependent mainly on patient tolerance and contraindications. These recommendations apply as long as the choice will not impose a substantial financial burden. Initial therapy with aspirin is appropriate for patients who cannot afford or cannot obtain the more effective antiplatelet agents (clopidogrel or aspirin-extended-release dipyridamole). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Aspirin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Clopidogrel'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Aspirin plus dipyridamole'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the optimal dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      is uncertain, there is no compelling evidence that any specific dose is more effective than another, and fewer gastrointestinal side effects and bleeding occur with lower doses (&le;325 mg a day). We recommend a dose of 50 to 100 mg daily when using aspirin for the secondary prevention of ischemic stroke (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dose of aspirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients having carotid endarterectomy, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (81 to 325 mg daily) started before surgery and continued indefinitely in the absence of a contraindication (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=see_link&amp;anchor=H93838520#H93838520\">",
"       \"Carotid endarterectomy\", section on 'Aspirin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aggrenox (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"       aspirin-extended-release dipyridamole",
"      </a>",
"      ) should not be used in patients who cannot tolerate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       Clopidogrel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      is an obvious alternative for patients who cannot tolerate aspirin.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"       Ticlopidine",
"      </a>",
"      should be reserved for patients intolerant of aspirin and clopidogrel. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Aspirin plus dipyridamole'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Clopidogrel'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Ticlopidine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with a noncardioembolic stroke or TIA, we recommend",
"      <strong>",
"       not",
"      </strong>",
"      using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      in combination for long-term stroke prevention, given the lack of greater efficacy compared with clopidogrel alone and the substantially increased risk of bleeding complications (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Aspirin plus clopidogrel'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      However, selected patients with a recent acute myocardial infarction, other acute coronary syndrome, or arterial stent placement are treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . Recommendations for combination antiplatelet therapy in these settings are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link\">",
"       \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link\">",
"       \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link\">",
"       \"Antiplatelet therapy after coronary artery stenting\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with recently symptomatic intracranial large artery disease, we suggest dual antiplatelet therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      for 90 days, followed by antiplatelet monotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H640139\">",
"       'Stroke subtypes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention of recurrent stroke in patients with atrial fibrillation is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/1\">",
"      Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/2\">",
"      Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/3\">",
"      Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology 2004; 62:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/4\">",
"      Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 2005; 62:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/5\">",
"      Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/6\">",
"      Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/7\">",
"      United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group. Br Med J (Clin Res Ed) 1988; 296:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/8\">",
"      Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration. Br Med J (Clin Res Ed) 1988; 296:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/9\">",
"      The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group. Lancet 1987; 2:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/10\">",
"      Johnson ES, Lanes SF, Wentworth CE 3rd, et al. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 1999; 159:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/11\">",
"      A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med 1991; 325:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/12\">",
"      Patrono C, Garc&iacute;a Rodr&iacute;guez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353:2373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/13\">",
"      Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e601S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/14\">",
"      Hirsh J, Dalen JE, Fuster V, et al. Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. Chest 1995; 108:247S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/15\">",
"      Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005; 95:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/16\">",
"      McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006; 119:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/17\">",
"      CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/18\">",
"      Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, Writing Committee Members, et al. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA \"boxed warning\": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010; 122:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/19\">",
"      Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/20\">",
"      Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/21\">",
"      Usman MH, Notaro LA, Nagarakanti R, et al. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am J Cardiol 2009; 103:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/22\">",
"      Amarenco P, Donnan GA. Should the MATCH results be extrapolated to all stroke patients and affect ongoing trials evaluating clopidogrel plus aspirin? Stroke 2004; 35:2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/23\">",
"      Liao JK. Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer? Circulation 2007; 115:1615.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical advisory: Secondary Prevention of Small Subcortical Strokes trial: NINDS stops treatment with combination antiplatelet therapy (clopidogrel plus aspirin) due to higher risk of major hemorrhage and death. www.nlm.nih.gov/databases/alerts/2011_ninds_stroke.html (Accessed on November 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/25\">",
"      SPS3 Investigators, Benavente OR, Hart RG, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012; 367:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/26\">",
"      Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005; 111:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/27\">",
"      Wong KS, Chen C, Fu J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010; 9:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/28\">",
"      Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011; 365:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/29\">",
"      Leonardi-Bee J, Bath PM, Bousser MG, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 2005; 36:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/30\">",
"      ESPRIT Study Group, Halkes PH, van Gijn J, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/31\">",
"      Lipton RB, Bigal ME, Kolodner KB, et al. Acetaminophen in the treatment of headaches associated with dipyridamole-aspirin combination. Neurology 2004; 63:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/32\">",
"      Diener HC, Darius H, Bertrand-Hardy JM, et al. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract 2001; 55:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/33\">",
"      Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004; 292:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/34\">",
"      Pfisterer, M. Intravenous dipyridamole for stress thallium-201 perfusion scintigraphy. Cardiovasc Imag 1992; 4:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/35\">",
"      Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/36\">",
"      Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke 2008; 39:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/37\">",
"      Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/38\">",
"      Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/39\">",
"      Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/40\">",
"      Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003; 289:2947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/41\">",
"      Matsumoto M. Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. Atheroscler Suppl 2005; 6:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/42\">",
"      Huang Y, Cheng Y, Wu J, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008; 7:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/43\">",
"      Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/44\">",
"      Mat&iacute;as-Guiu J, Ferro JM, Alvarez-Sab&iacute;n J, et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Stroke 2003; 34:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/45\">",
"      Culebras A, Rotta-Escalante R, Vila J, et al. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. Neurology 2004; 62:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/46\">",
"      Costa J, Ferro JM, Matias-Guiu J, et al. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev 2005; :CD004296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/47\">",
"      Anderson DC, Goldstein LB. Aspirin: it's hard to beat. Neurology 2004; 62:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/35/2618/abstract/48\">",
"      Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:227.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1086 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-E3D6416427-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_35_2618=[""].join("\n");
var outline_f2_35_2618=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ASPIRIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dose of aspirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Toxicity and risk of bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLOPIDOGREL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Side effects of clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Aspirin plus clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H640139\">",
"      - Stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIPYRIDAMOLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Side effects of dipyridamole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cardiac effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Aspirin plus dipyridamole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Aspirin plus extended-release dipyridamole versus clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OTHER AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ticlopidine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Side effects of ticlopidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105978174\">",
"      Cilostazol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Triflusal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CHOOSING INITIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=related_link\">",
"      Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31688?source=related_link\">",
"      Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42378?source=related_link\">",
"      Cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=related_link\">",
"      Carotid endarterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2010?source=related_link\">",
"      Intracranial large artery atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19401?source=related_link\">",
"      Nonresponse and resistance to aspirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/53/19286?source=related_link\">",
"      Patient information: Ischemic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/37/36435?source=related_link\">",
"      Patient information: Medicines after an ischemic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/18/20772?source=related_link\">",
"      Patient information: Transient ischemic attack (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_35_2619="Differential diagnosis for medial elbow pain";
var content_f2_35_2619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis for medial elbow pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Epicondylitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cubital tunnel syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ulnar neuritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       UCL insufficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Little league elbow",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inflammatory arthritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cervical radiculopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thoracic outlet syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Myofascial pain",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     UCL: ulnar collateral ligament",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_35_2619=[""].join("\n");
var outline_f2_35_2619=null;
var title_f2_35_2620="TEE approach to cardioversion of AF";
var content_f2_35_2620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Advantages and disadvantages of the transesophageal echocardiography-guided approach to cardioversion of patients with atrial fibrillation undergoing cardioversion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transesophageal echocardiography (TEE) should be able to detect left atrial appendage thrombi, which increase the risk of embolic stroke after electrical cardioversion, thus sparing patients with thrombi from undergoing cardioversion.",
"       </td>",
"       <td>",
"        TEE is performed without any definitive guidelines about who should receive the procedure (high versus low risk)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In the majority of patients without left atrial appendage thrombi, earlier cardioversion may shorten the period of anticoagulation and lower the corresponding risk of bleeding complications",
"       </td>",
"       <td>",
"        Residual thrombus on repeat TEE may diminish the cost-effectiveness of the TEE-guided approach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A TEE-guided approach may prove more cost-effective owing to the reduction in laboratory monitoring costs and the reduction in bleeding complications",
"       </td>",
"       <td>",
"        Transesophageal echocardiography requires a level III-trained physician and availability of expensive echocardiographic machines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Earlier cardioversion is believed to increase the likelihood of a successful return to and maintenance of sinus rhythm",
"       </td>",
"       <td>",
"        Transesophageal echocardiography may miss thrombi that may embolize after cardioversion. In contrast, TEE may render false positive results by erroneously indentifying spontaneous echocardiographic contrast, sludge, multilobed appendages or pectinate muscles as thrombus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: The American College of Cardiology. J Am Coll of Cardiol 2001; 37:691-704.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_35_2620=[""].join("\n");
var outline_f2_35_2620=null;
var title_f2_35_2621="GI symptoms in scleroderma";
var content_f2_35_2621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Manifestations of gut involvement in systemic sclerosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Site",
"      </td>",
"      <td class=\"subtitle1\">",
"       Disorder",
"      </td>",
"      <td class=\"subtitle1\">",
"       Symptom",
"      </td>",
"      <td class=\"subtitle1\">",
"       Investigation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Mouth",
"      </td>",
"      <td>",
"       Tight skin",
"      </td>",
"      <td>",
"       Cosmetic",
"      </td>",
"      <td>",
"       None",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dental caries",
"      </td>",
"      <td>",
"       Toothache",
"      </td>",
"      <td>",
"       Dental x-ray",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sicca syndrome",
"      </td>",
"      <td>",
"       Dry mouth",
"      </td>",
"      <td>",
"       Salivary gland biopsy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Esophagus",
"      </td>",
"      <td>",
"       Hypomotility",
"      </td>",
"      <td>",
"       Dysphagia",
"      </td>",
"      <td>",
"       Manometry",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reflux esophagitis",
"      </td>",
"      <td>",
"       Heartburn/dysphagia",
"      </td>",
"      <td>",
"       Endoscopy/24 hour pH study",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stricture",
"      </td>",
"      <td>",
"       Dysphagia",
"      </td>",
"      <td>",
"       Barium swallow, endoscopy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Stomach",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Gastric paresis",
"      </td>",
"      <td>",
"       Anorexia",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Scintigram",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nausea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Early satiety",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NSAID related ulcer",
"      </td>",
"      <td>",
"       Dyspepsia",
"      </td>",
"      <td>",
"       Endoscopy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"9\">",
"       Small bowel",
"      </td>",
"      <td>",
"       Hypomotility",
"      </td>",
"      <td>",
"       Weight loss",
"      </td>",
"      <td>",
"       Barium follow-through",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stasis",
"      </td>",
"      <td>",
"       Postprandial bloating",
"      </td>",
"      <td>",
"       14C glycocholate or hydrogen breath test",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Bacterial overgrowth",
"      </td>",
"      <td>",
"       Malabsorption",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Jejunal aspiration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Steatorrhea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nausea, cramps",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pseudo-obstruction",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Abdominal pain distension",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Plain abdominal x-ray",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NSAID ulceration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Pneumatosis intestinalis",
"      </td>",
"      <td>",
"       Bloody diarrhea",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Plain abdominal x-ray",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Benign pneumo-peritoneum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Large bowel",
"      </td>",
"      <td>",
"       Hypomotility",
"      </td>",
"      <td>",
"       Alternating constipation and diarrhea",
"      </td>",
"      <td>",
"       Barium enema",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Colonic pseudo diverticula",
"      </td>",
"      <td>",
"       Rare perforation",
"      </td>",
"      <td>",
"       Barium enema",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pseudo-obstruction",
"      </td>",
"      <td>",
"       Abdominal pain distension",
"      </td>",
"      <td>",
"       Plain abdominal x-ray",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anus",
"      </td>",
"      <td>",
"       Sphincter involvement",
"      </td>",
"      <td>",
"       Fecal incontinence",
"      </td>",
"      <td>",
"       Rectal manometry",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_35_2621=[""].join("\n");
var outline_f2_35_2621=null;
var title_f2_35_2622="Cross-reactivity among related food allergens";
var content_f2_35_2622=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F77726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F77726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Approximate rates of clinical cross-reactivity among related food allergens",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 361px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CMA: cow's milk allergy; OAS: oral allergy syndrome (food-pollen syndrome).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_35_2622=[""].join("\n");
var outline_f2_35_2622=null;
var title_f2_35_2623="Esophageal web Ba swallow";
var content_f2_35_2623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal web on barium swallow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 204px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This modified barium swallow, obtained in a 45-year-old man with dysphagia, demonstrates an asymmetric esophageal web arising from the right side of the upper esophagus (arrow). Note the impression in the midpharynx produced by the cricopharyngeus muscle (CP).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_35_2623=[""].join("\n");
var outline_f2_35_2623=null;
